<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005019.pub4" GROUP_ID="RENAL" ID="881504082315532705" MERGED_FROM="" MODIFIED="2015-01-21 13:51:01 +1100" MODIFIED_BY="Narelle Willis" REVIEW_NO="052" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2015-01-21 13:51:01 +1100" MODIFIED_BY="Narelle Willis">
<TITLE>HMG CoA reductase inhibitors (statins) for kidney transplant recipients</TITLE>
<CONTACT>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology and Epidemiology</DEPARTMENT>
<ORGANISATION>Mario Negri Sud Foundation</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Santa Maria Imbaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-01-21 13:49:38 +1100" MODIFIED_BY="Narelle Willis">
<PERSON ID="19787" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Suetonia</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Palmer</LAST_NAME>
<SUFFIX>MBChB</SUFFIX>
<POSITION/>
<EMAIL_1>suetonia.palmer@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2>PO Box 4345</ADDRESS_2>
<CITY>Christchurch</CITY>
<ZIP>8140</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 21626008</PHONE_1>
<PHONE_2/>
<FAX_1>+64 3 3253368</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16132" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sankar</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Navaneethan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>navanes@ccf.org</EMAIL_1>
<EMAIL_2>sankardass@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology and Hypertension</DEPARTMENT>
<ORGANISATION>Glickman Urological and Kidney Institute, Cleveland Clinic</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cleveland</CITY>
<ZIP>44195</ZIP>
<REGION>OH</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 216 6369230</PHONE_1>
<PHONE_2/>
<FAX_1>+1 216 4449378</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4552" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1>
<EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Edward Ford Building A27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19789" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Vlado</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perkovic</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>vperkovic@georgeinstitute.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Renal and Metabolic Division</DEPARTMENT>
<ORGANISATION>The George Institute for International Health</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Camperdown</CITY>
<ZIP/>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 99934551</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 99934502</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16113" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Johnson</LAST_NAME>
<SUFFIX/>
<POSITION>Nephrologist</POSITION>
<EMAIL_1>david_johnson@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>Ipswich Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 5080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 5480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="60A7CD7482E26AA20029B8549EA567DA" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sagar</FIRST_NAME>
<MIDDLE_INITIALS>U</MIDDLE_INITIALS>
<LAST_NAME>Nigwekar</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>sagarnigs@gmail.com</EMAIL_1>
<EMAIL_2>snigwekar@partners.org</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Brigham and Women's Hospital, Massachusetts General Hospital, Scholars in Clinical Sciences Program</DEPARTMENT>
<ORGANISATION>Harvard Medical School</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP/>
<REGION>MA</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="50537534288058682062110419044257" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jorgen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hegbrant</LAST_NAME>
<SUFFIX/>
<POSITION>Chief Medical Officer</POSITION>
<EMAIL_1>Jorgen.Hegbrant@diaverum.com</EMAIL_1>
<EMAIL_2>rs07@diaverum.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Office</DEPARTMENT>
<ORGANISATION>Diaverum Renal Services Group</ORGANISATION>
<ADDRESS_1>PO Box 4167</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP>SE-227 22</ZIP>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1>+46 708 11 93 44</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology and Epidemiology</DEPARTMENT>
<ORGANISATION>Mario Negri Sud Foundation</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Santa Maria Imbaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-01-21 13:49:38 +1100" MODIFIED_BY="Narelle Willis">
<UP_TO_DATE>
<DATE DAY="29" MONTH="2" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="2" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="8" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-01-21 13:51:01 +1100" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-01-21 13:50:40 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="21" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>Feedback incorporated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-21 13:51:01 +1100" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-01-21 13:51:01 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="15" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Updated and conclusions amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-21 13:50:56 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="4" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Updated search on February 29, 2012. Results and conclusions updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-01-21 13:50:58 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="4" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Author added: Palmer SC</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-01-21 13:50:52 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="21" MONTH="12" YEAR="2010"/>
<DESCRIPTION>
<P>Search strategies revised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-07 13:40:12 +1100" MODIFIED_BY="Narelle S Willis">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-11-27 14:29:04 +1100" MODIFIED_BY="Suetonia Palmer">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-11-27 14:29:04 +1100" MODIFIED_BY="Suetonia Palmer">
<SOURCE MODIFIED="2013-11-27 14:29:04 +1100" MODIFIED_BY="Suetonia Palmer">
<NAME>Suetonia Palmer received a fellowship from the Consorzio Mario Negri Sud from an unrestricted grant by Amgen Dompe</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-14 08:10:14 +1000" MODIFIED_BY="Gail Y Higgins">
<SUMMARY MODIFIED="2013-12-19 08:58:30 +1100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-25 13:40:57 +1000" MODIFIED_BY="Narelle S Willis">HMG CoA reductase inhibitors (statins) for kidney transplant recipients</TITLE>
<SUMMARY_BODY MODIFIED="2013-12-19 08:58:30 +1100" MODIFIED_BY="[Empty name]">
<P>Kidney transplant patients experience heart disease more often than the general population. Statins have been shown to decrease cholesterol, heart attacks, strokes and deaths for the general population. The aim of this review was to find out whether statins prevent death and complications from heart disease in people who have had a kidney transplant. We included 17 studies in 3282 adults with a functioning kidney transplant which compared statin therapy to a placebo or standard treatment. Based largely on information from a single, large and well-conducted study, statins may reduce complications from heart disease although information from the available research is imprecise. The effects of statin treatment on death overall, stroke, kidney function and side-effects are uncertain in people with a kidney transplant. Large additional studies of statin therapy may improve our confidence that statin treatment can safely prevent serious complications from heart disease for people who have a kidney transplant.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-01-15 14:52:15 +1100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-12-19 11:49:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>People with chronic kidney disease (CKD) have higher risks of cardiovascular disease compared to the general population. Specifically, cardiovascular deaths account most deaths in kidney transplant recipients. Statins are a potentially beneficial intervention for kidney transplant patients given their established benefits in patients at risk of cardiovascular disease in the general population. This is an update of a review first published in 2009.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-12-19 12:05:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>We aimed to evaluate the benefits (reductions in all-cause and cardiovascular mortality, major cardiovascular events, myocardial infarction and stroke, and progression of CKD to requiring dialysis) and harms (muscle or liver dysfunction, withdrawal, cancer) of statins compared to placebo, no treatment, standard care, or another statin in adults with CKD who have a functioning kidney transplant.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-18 16:47:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials Search Co-ordinator using search terms relevant to this review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-12-19 11:50:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care, or statins on mortality, cardiovascular events, kidney function and toxicity in kidney transplant recipients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-12-18 16:47:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>Two authors independently extracted data and assessed risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes (lipids, glomerular filtration rate (GFR), proteinuria) and relative risk (RR) for dichotomous outcomes (major cardiovascular events, mortality, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, elevated muscle or liver enzymes, withdrawal due to adverse events, cancer, end-stage kidney disease (ESKD), acute allograft rejection) together with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-01-15 14:52:15 +1100" MODIFIED_BY="[Empty name]">
<P>We identified 22 studies (3465 participants); 17 studies (3282 participants) compared statin with placebo or no treatment, and five studies (183 participants) compared two different statin regimens.</P>
<P>From data generally derived from a single high-quality study, it was found that statins may reduce major cardiovascular events (1 study, 2102 participants: RR 0.84, CI 0.66 to 1.06), cardiovascular mortality (4 studies, 2322 participants: RR 0.68, CI 0.45 to 1.01), and fatal or non-fatal myocardial infarction (1 study, 2102 participants: RR 0.70, CI 0.48 to 1.01); although effect estimates lack precision and include the possibility of no effect.</P>
<P>Statins had uncertain effects on all-cause mortality (6 studies, 2760 participants: RR 1.08, CI 0.63 to 1.83); fatal or non-fatal stroke (1 study, 2102 participants: RR 1.18, CI 0.85 to 1.63); creatine kinase elevation (3 studies, 2233 participants: RR 0.86, CI 0.39 to 1.89); liver enzyme elevation (4 studies, 608 participants: RR 0.62, CI 0.33 to 1.19); withdrawal due to adverse events (9 studies, 2810 participants: RR 0.89, CI 0.74 to 1.06); and cancer (1 study, 2094 participants: RR 0.94, CI 0.82 to 1.07).</P>
<P>Statins significantly reduced serum total cholesterol (12 studies, 3070 participants: MD -42.43 mg/dL, CI -51.22 to -33.65); low-density lipoprotein cholesterol (11 studies, 3004 participants: MD -43.19 mg/dL, CI -52.59 to -33.78); serum triglycerides (11 studies, 3012 participants: MD -27.28 mg/dL, CI -34.29 to -20.27); and lowered high-density lipoprotein cholesterol (11 studies, 3005 participants: MD -5.69 mg/dL, CI -10.35 to -1.03).</P>
<P>Statins had uncertain effects on kidney function: ESKD (6 studies, 2740 participants: RR 1.14, CI 0.94 to 1.37); proteinuria (2 studies, 136 participants: MD -0.04 g/24 h, CI -0.17 to 0.25); acute allograft rejection (4 studies, 582 participants: RR 0.88, CI 0.61 to 1.28); and GFR (1 study, 62 participants: MD -1.00 mL/min, CI -9.96 to 7.96).</P>
<P>Due to heterogeneity in comparisons, data directly comparing differing statin regimens could not be meta-analysed. Evidence for statins in people who have had a kidney transplant were sparse and lower quality due to imprecise effect estimates and provided limited systematic evaluation of treatment harm.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-12-19 08:58:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-04-14 08:10:14 +1000" MODIFIED_BY="Gail Y Higgins">
<BACKGROUND MODIFIED="2013-12-19 12:04:04 +1100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-12-19 12:03:18 +1100" MODIFIED_BY="[Empty name]">
<P>Kidney transplantation numbers are steadily increasing worldwide and survival rates are improving as a consequence of the adoption of more effective immunosuppressive regimens (<LINK REF="REF-USRDS-2011" TYPE="REFERENCE">USRDS 2011</LINK>). Cardiovascular disease still accounts for the majority of deaths in kidney transplant recipients (<LINK REF="REF-Jardine-2011" TYPE="REFERENCE">Jardine 2011</LINK>; <LINK REF="REF-Kasiske-1996" TYPE="REFERENCE">Kasiske 1996</LINK>; <LINK REF="REF-NKF-2002" TYPE="REFERENCE">NKF 2002</LINK>; <LINK REF="REF-USRDS-2011" TYPE="REFERENCE">USRDS 2011</LINK>). Studies conducted in the general population have demonstrated that dyslipidaemia (including increased total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol; and low, high-density lipoprotein (HDL) cholesterol levels) is a component of the causal pathway leading to cardiovascular mortality. As a consequence, statins have become broadly adopted as the main treatment for high cholesterol levels in the general population, following the results of major studies which demonstrated their impact on cardiovascular and all-cause mortality (<LINK REF="REF-ALLHAT-2002" TYPE="REFERENCE">ALLHAT 2002</LINK>; <LINK REF="REF-HPS-2003" TYPE="REFERENCE">HPS 2003</LINK>; <LINK REF="REF-JUPITER-2008" TYPE="REFERENCE">JUPITER 2008</LINK>; <LINK REF="REF-Sever-2003" TYPE="REFERENCE">Sever 2003</LINK>; <LINK REF="REF-Shepherd-1995" TYPE="REFERENCE">Shepherd 1995</LINK>). Recent clinical studies and analyses from earlier larger studies have confirmed the cardioprotective effects of statins in people with chronic kidney disease (CKD) (<LINK REF="REF-SHARP-2011" TYPE="REFERENCE">SHARP 2011</LINK>).</P>
</CONDITION>
<THEORY MODIFIED="2013-12-19 12:04:04 +1100" MODIFIED_BY="[Empty name]">
<P>Statins may modulate the risk of transplant rejection by decreasing inflammation, enhancing endothelial function, inhibiting smooth muscle proliferation, and exerting direct antithrombotic effects. These pleiotropic effects noted in clinical and laboratory studies suggested possible benefits of statins on acute allograft rejection. In kidney transplant recipients, where both systemic factors and immunosuppressive regimens play a role in changing cholesterol metabolism (<LINK REF="REF-Claesson-1998" TYPE="REFERENCE">Claesson 1998</LINK>; <LINK REF="REF-Cosio-2002" TYPE="REFERENCE">Cosio 2002</LINK>; <LINK REF="REF-Flechner-2002" TYPE="REFERENCE">Flechner 2002</LINK>; <LINK REF="REF-Hilbrands-1995" TYPE="REFERENCE">Hilbrands 1995</LINK>, <LINK REF="REF-Groth-1999" TYPE="REFERENCE">Groth 1999</LINK>; <LINK REF="REF-John-1999" TYPE="REFERENCE">John 1999</LINK>; <LINK REF="REF-Massy-2001" TYPE="REFERENCE">Massy 2001</LINK>; <LINK REF="REF-Mathis-2004" TYPE="REFERENCE">Mathis 2004</LINK>, <LINK REF="REF-Raine-1988" TYPE="REFERENCE">Raine 1988</LINK>; <LINK REF="REF-Satterthwaite-1998" TYPE="REFERENCE">Satterthwaite 1998</LINK>), cohort studies have indicated that increased total cholesterol, LDL cholesterol and triglycerides are independent risk factors for allograft rejection and that statin administration is associated with improved patient survival (<LINK REF="REF-Aakhus-1999" TYPE="REFERENCE">Aakhus 1999</LINK>; <LINK REF="REF-Aker-1998" TYPE="REFERENCE">Aker 1998</LINK>; <LINK REF="REF-Vathsala-1989" TYPE="REFERENCE">Vathsala 1989</LINK>). Additionally, retrospective studies have shown that increased cholesterol and triglycerides are also independent risk factors for allograft rejection in kidney transplant recipients (<LINK REF="REF-Del-Castillo-2004" TYPE="REFERENCE">Del Castillo 2004</LINK>; <LINK REF="REF-Isoneimi-1994" TYPE="REFERENCE">Isoneimi 1994</LINK>; <LINK REF="REF-Massy-1996" TYPE="REFERENCE">Massy 1996</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-12-19 09:05:14 +1100" MODIFIED_BY="[Empty name]">
<P>By extrapolation from the results of these observational data and available randomised controlled trials (RCTs) conducted in the general population, statins have been widely used in kidney transplant recipients. However, there are well recognised discrepancies between the results of observational and study data such that an assessment of the effect of statins on survival in kidney transplant recipients needs to be assessed in available RCTs specifically conducted in this population. Since individual studies of statins in transplant recipients may be underpowered to detect treatment effects on mortality, cardiovascular events and kidney outcomes, we have updated our earlier systematic review and meta-analysis of all available RCTs (<LINK REF="REF-Navaneethan-2009c" TYPE="REFERENCE">Navaneethan 2009c</LINK>) to February 2012.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-12-19 12:05:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>We aimed to evaluate the benefits (reductions in all-cause and cardiovascular mortality, major cardiovascular events, myocardial infarction and stroke, and progression of CKD to requiring dialysis) and harms (muscle or liver dysfunction, withdrawal, cancer) of statins compared to placebo, no treatment, standard care, or another statin in adults with CKD who have a functioning kidney transplant.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-01-15 13:02:59 +1100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-19 12:07:05 +1100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-12-19 12:06:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>RCTs and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) that evaluated the benefits and harms of statins in adults with a functioning kidney transplant. The first period of randomised cross-over studies was included. We excluded studies of fewer than eight weeks' duration as such studies were unlikely to permit detection of mortality or cardiovascular outcomes related to statin therapy (<LINK REF="REF-Briel-2006" TYPE="REFERENCE">Briel 2006</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-19 12:07:05 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Studies or subgroups of studies enrolling adult kidney transplant recipients were included irrespective of presence of cardiovascular disease at baseline.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Patients with stages 1-5 CKD and on dialysis (K-DOQI stage 5 on dialysis) were excluded as these have been evaluated in separate reviews (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>; <LINK REF="REF-Palmer-2013" TYPE="REFERENCE">Palmer 2013</LINK>).</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-12-18 16:16:14 +1100" MODIFIED_BY="Narelle S Willis">
<P>We included studies comparing statins with placebo, no treatment or standard care, or another statin. We excluded studies where a statin was compared with a second non-statin regimen including fibrate therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-12-18 15:44:07 +1100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-21 09:48:55 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Cardiovascular mortality</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-12-18 15:44:07 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>All-cause mortality</LI>
<LI>Major cardiovascular events</LI>
<LI>Fatal and non-fatal myocardial infarction</LI>
<LI>Fatal and non-fatal stroke</LI>
<LI>Adverse events attributable to treatment</LI>
<LI>Elevated creatine kinase</LI>
<LI>Elevated liver enzymes</LI>
<LI>Withdrawal due to adverse events</LI>
<LI>Cancer</LI>
<LI>End of treatment lipid levels</LI>
<OL>
<LI>Total cholesterol</LI>
<LI>LDL cholesterol</LI>
<LI>HDL cholesterol</LI>
<LI>Triglycerides</LI>
</OL>
<LI>End-stage kidney disease (ESKD)</LI>
<LI>Acute rejection</LI>
<LI>End of treatment proteinuria</LI>
<LI>End of treatment glomerular filtration rate (GFR)</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-19 12:08:36 +1100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-12-19 12:08:36 +1100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Renal Group's Specialised Register through contact with the Trials' Search Coordinator (to 29 February 2012) using search terms relevant to this review.</P>
<P>The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from the following sources.</P>
<OL>
<LI>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-12-18 16:35:59 +1100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reference lists of clinical practice guidelines, review articles and relevant studies.</LI>
<LI>Reference lists of abstracts from nephrology scientific meetings.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-01-15 13:02:59 +1100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-12-19 09:11:51 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Initial review (2009)</HEADING>
<P>The review (<LINK REF="REF-Navaneethan-2009c" TYPE="REFERENCE">Navaneethan 2009c</LINK>) was initially undertaken by six authors (SDN, SN, VP, DJ, JC, GFMS). The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened independently by three authors (SDN, SN, GFMS) who excluded studies that were not applicable. However, studies and reviews that might have included relevant data or information on studies were retained initially. Two authors (SDN, SN) independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. Disagreements were resolved in consultation with GFMS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Updated review (2013)</HEADING>
<P>The update was performed by two independent authors (SDN, SCP) using methods from earlier versions of the review with support from the remaining authors. The same two authors independently screened abstracts retrieved by electronic searches to identify potentially relevant citations for detailed study in full text format. Studies that might include relevant data or information on studies involving statins were initially retained. Studies published in non-English journals were translated before assessment for inclusion when a non-English abstract was provided. Disagreements were resolved in consultation with GFMS.</P>
</SUBSECTION>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-12-19 09:12:55 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Initial review (2009)</HEADING>
<P>Data extraction was carried out by the same authors independently using the standard data extraction forms. Studies reported in non-English language journals were translated before assessment. When more than one publication of one study existed, the publication with the most complete data was included. Disagreements were resolved in consultation with GFMS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Updated review to (2013)</HEADING>
<P>Authors independently extracted data from the eligible studies using standard data extraction forms. Where more than one publication of one study existed, the publication with the most complete data was included. Disagreements between authors were resolved in consultation with GFMS.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-03-07 12:02:34 +1100" MODIFIED_BY="Narelle S Willis">
<P>The following items were independently assessed by two authors (SDN, SCP) using the risk of bias assessment tool (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-12-19 12:10:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>For dichotomous outcomes (major cardiovascular events, mortality, adverse events, ESKD, acute rejection), treatment effects were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (lipid parameters, proteinuria, creatinine clearance), the mean difference (MD) was used.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2012-03-07 11:46:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>Any further information required from the authors of the studies was requested by written correspondence and relevant information obtained in this manner was included in the review. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-12-19 09:13:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Heterogeneity was analysed using the Cochran Q (Chi², N-1 degrees of freedom) and the I² statistic, with a P of 0.05 used for statistical significance.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-12-19 12:11:03 +1100" MODIFIED_BY="Narelle S Willis">
<P>To assess potential bias from small-study effects, we constructed funnel plots for the log RR in individual studies against the standard error of the RR. We carried out formal statistical assessment of funnel plot asymmetry with the Egger regression test (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>). We conducted analyses using Comprehensive Meta-Analysis (Version 2, Biostat, Englewood, NJ, 2005).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-12-19 12:11:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data were summarised using the Der Simonian-Laird random-effects model, but the fixed-effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
<P>We summarised the quality of the evidence together with absolute treatment effects for mortality and cardiovascular events based on estimated baseline risks using Grading of Recommendations Assessment Development and Evaluation (GRADE) guidelines (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) Absolute numbers of adults with a kidney transplant who had cardiovascular events or adverse events avoided or incurred with statin therapy were estimated using the risk estimate for the outcome (and associated 95% CI) obtained from the corresponding meta-analysis together with the absolute population risk estimated from previously published observational studies (<LINK REF="REF-ANZDATA-2010" TYPE="REFERENCE">ANZDATA 2010</LINK>; <LINK REF="REF-Lentine-2005" TYPE="REFERENCE">Lentine 2005</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-01-15 13:02:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>We conducted prespecified subgroup analyses to explore potential sources of heterogeneity in modifying estimates of the effects of statins in the studies when significant heterogeneity was present. We planned subgroup analyses according to the following participant, intervention, or study-related characteristics, when subgroups possessed four or more independent studies (statin type, statin dose (equivalent to simvastatin)), baseline cholesterol (&lt; 230 mg/dL versus &#8805; 230 mg/dL), age (&lt; 55 years versus &#8805; 55 years), proportion with diabetes (&#8805; 20% versus &lt; 20%), or adequacy of allocation concealment.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-04-14 08:10:14 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDY_DESCRIPTION MODIFIED="2014-04-14 08:10:14 +1000" MODIFIED_BY="Gail Y Higgins">
<SEARCH_RESULTS MODIFIED="2014-04-14 08:07:48 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Our initial review (<LINK REF="REF-Navaneethan-2009c" TYPE="REFERENCE">Navaneethan 2009c</LINK>) included 16 studies. We reviewed in detail an additional 80 reports that were identified by an updated search conducted in February 2012 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Six new studies were included in this review update review (<LINK REF="STD-Celik-2000a" TYPE="STUDY">Celik 2000a</LINK>; <LINK REF="STD-Raiola-1998" TYPE="STUDY">Raiola 1998</LINK>; <LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>; <LINK REF="STD-Vergoulas-1999" TYPE="STUDY">Vergoulas 1999</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-04-14 08:07:48 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Overall we have included 22 studies, enrolling 3465 participants in the review update. Seventeen studies (3282 participants) compared statin with placebo (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Arnadottir-1994" TYPE="STUDY">Arnadottir 1994</LINK>; <LINK REF="STD-Bill-1995" TYPE="STUDY">Bill 1995</LINK>; <LINK REF="STD-Cofan-2002" TYPE="STUDY">Cofan 2002</LINK>; <LINK REF="STD-Hausberg-2001" TYPE="STUDY">Hausberg 2001</LINK>; <LINK REF="STD-Kasiske-2001" TYPE="STUDY">Kasiske 2001</LINK>; <LINK REF="STD-Katznelson-1996" TYPE="STUDY">Katznelson 1996</LINK>; <LINK REF="STD-Lepre-1999" TYPE="STUDY">Lepre 1999</LINK>; <LINK REF="STD-Martinez-Hernandez-1993" TYPE="STUDY">Martinez Hernandez 1993</LINK>; <LINK REF="STD-Melchor-1998" TYPE="STUDY">Melchor 1998</LINK>; <LINK REF="STD-Renders-2001" TYPE="STUDY">Renders 2001</LINK>; <LINK REF="STD-Sahu-2001" TYPE="STUDY">Sahu 2001</LINK>; <LINK REF="STD-Santos-2001" TYPE="STUDY">Santos 2001</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>; <LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>) and five studies (183 participants) compared two different statin regimens (<LINK REF="STD-Castelao-1993" TYPE="STUDY">Castelao 1993</LINK>; <LINK REF="STD-Celik-2000a" TYPE="STUDY">Celik 2000a</LINK>; <LINK REF="STD-Raiola-1998" TYPE="STUDY">Raiola 1998</LINK>; <LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>; <LINK REF="STD-Vergoulas-1999" TYPE="STUDY">Vergoulas 1999</LINK>). Notably, the <LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK> study was a large and well-conducted double-blinded RCT conducted in transplant patients and most data for the meta-analyses are derived from this study.</P>
<P>Four studies were randomised cross-over studies (<LINK REF="STD-Celik-2000a" TYPE="STUDY">Celik 2000a</LINK>; <LINK REF="STD-Martinez-Hernandez-1993" TYPE="STUDY">Martinez Hernandez 1993</LINK>; <LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>; <LINK REF="STD-Vergoulas-1999" TYPE="STUDY">Vergoulas 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Statin versus placebo or no treatment</HEADING>
<P>Studies varied in sample size (median 48 participants; range 20 to 2102) and were generally small (all but one study (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>) had fewer than 1000 participants). The median statin dose (equivalent to simvastatin) was 10 mg (range 5 to 40 mg).</P>
<P>Statin interventions included atorvastatin or cerivastatin (<LINK REF="STD-Renders-2001" TYPE="STUDY">Renders 2001</LINK>); fluvastatin (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Hausberg-2001" TYPE="STUDY">Hausberg 2001</LINK>; <LINK REF="STD-Melchor-1998" TYPE="STUDY">Melchor 1998</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>); lovastatin (<LINK REF="STD-Bill-1995" TYPE="STUDY">Bill 1995</LINK>; <LINK REF="STD-Sahu-2001" TYPE="STUDY">Sahu 2001</LINK>); pravastatin (<LINK REF="STD-Cofan-2002" TYPE="STUDY">Cofan 2002</LINK>; <LINK REF="STD-Katznelson-1996" TYPE="STUDY">Katznelson 1996</LINK>); rosuvastatin (<LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>); or simvastatin (<LINK REF="STD-Arnadottir-1994" TYPE="STUDY">Arnadottir 1994</LINK>; <LINK REF="STD-Kasiske-2001" TYPE="STUDY">Kasiske 2001</LINK>; <LINK REF="STD-Lepre-1999" TYPE="STUDY">Lepre 1999</LINK>; <LINK REF="STD-Martinez-Hernandez-1993" TYPE="STUDY">Martinez Hernandez 1993</LINK>; <LINK REF="STD-Santos-2001" TYPE="STUDY">Santos 2001</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>). Median follow-up duration was four months (range 2 to 61 months); four studies had follow-up of 12 months or more (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Cofan-2002" TYPE="STUDY">Cofan 2002</LINK>; <LINK REF="STD-Hausberg-2001" TYPE="STUDY">Hausberg 2001</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>). Two studies included participants who had no histories of cardiovascular disease (<LINK REF="STD-Cofan-2002" TYPE="STUDY">Cofan 2002</LINK>; <LINK REF="STD-Hausberg-2001" TYPE="STUDY">Hausberg 2001</LINK>). Median baseline serum LDL cholesterol was 257 mg/dL (range 159 to 319 mg/dL). No study was a post-hoc subgroup analysis of a larger study in a broader population. Four studies (<LINK REF="STD-Cofan-2002" TYPE="STUDY">Cofan 2002</LINK>; <LINK REF="STD-Hausberg-2001" TYPE="STUDY">Hausberg 2001</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>) excluded people with diabetes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statin versus another statin</HEADING>
<P>Five studies compared two different statin regimens. Four studies compared two different statins: lovastatin versus simvastatin (<LINK REF="STD-Castelao-1993" TYPE="STUDY">Castelao 1993</LINK>); atorvastatin versus fluvastatin <LINK REF="STD-Raiola-1998" TYPE="STUDY">Raiola 1998</LINK>); simvastatin versus pravastatin (<LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>); and lovastatin versus fluvastatin (<LINK REF="STD-Vergoulas-1999" TYPE="STUDY">Vergoulas 1999</LINK>); and one compared a lower and higher dose of simvastatin (<LINK REF="STD-Celik-2000a" TYPE="STUDY">Celik 2000a</LINK>). Median duration was 12 months (range 2 to 12 months). All studies had a small sample size (median 32 participants; range 20 to 51). Insufficient data were available to conduct meta-analyses.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-04-14 08:10:14 +1000" MODIFIED_BY="Gail Y Higgins">
<P>We excluded 35 studies: 10 did not evaluate an appropriate intervention (<LINK REF="STD-Bagdade-1979" TYPE="STUDY">Bagdade 1979</LINK>; <LINK REF="STD-Blum-2000" TYPE="STUDY">Blum 2000</LINK>; <LINK REF="STD-Curtis-1982" TYPE="STUDY">Curtis 1982</LINK>; <LINK REF="STD-Hilbrands-1993" TYPE="STUDY">Hilbrands 1993</LINK>; <LINK REF="STD-Ichimaru-2001" TYPE="STUDY">Ichimaru 2001</LINK>; <LINK REF="STD-Imamura-2005" TYPE="STUDY">Imamura 2005</LINK>; <LINK REF="STD-Kahan_x002d_301-2000" TYPE="STUDY">Kahan-301 2000</LINK>; <LINK REF="STD-LANDMARK-2-2009" TYPE="STUDY">LANDMARK 2 2009</LINK>; <LINK REF="STD-Ok-1996" TYPE="STUDY">Ok 1996</LINK>; <LINK REF="STD-Wissing-2006" TYPE="STUDY">Wissing 2006</LINK>); 10 compared a statin with an active non-statin intervention (<LINK REF="STD-Blechman_x002d_Krom-2000" TYPE="STUDY">Blechman-Krom 2000</LINK>; <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>; <LINK REF="STD-Cheng-1995" TYPE="STUDY">Cheng 1995</LINK>; <LINK REF="STD-Gonzalez_x002d_Molina-1996" TYPE="STUDY">Gonzalez-Molina 1996</LINK>; <LINK REF="STD-Lal-1992" TYPE="STUDY">Lal 1992</LINK>; <LINK REF="STD-Lal-1996" TYPE="STUDY">Lal 1996</LINK>; <LINK REF="STD-Lal-1998" TYPE="STUDY">Lal 1998</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>; <LINK REF="STD-Vasquez-2004" TYPE="STUDY">Vasquez 2004</LINK>; <LINK REF="STD-White-1996" TYPE="STUDY">White 1996</LINK>); seven did not use a randomised study design (<LINK REF="STD-Capone-1999" TYPE="STUDY">Capone 1999</LINK>; <LINK REF="STD-Lopau-2006" TYPE="STUDY">Lopau 2006</LINK>; <LINK REF="STD-Markell-1995" TYPE="STUDY">Markell 1995</LINK>; <LINK REF="STD-Nart-2009" TYPE="STUDY">Nart 2009</LINK>; <LINK REF="STD-Nicholson-1993" TYPE="STUDY">Nicholson 1993</LINK>; <LINK REF="STD-Ruiz-2006" TYPE="STUDY">Ruiz 2006</LINK>; <LINK REF="STD-Turk-2001" TYPE="STUDY">Turk 2001</LINK>); one was terminated (<LINK REF="STD-Renders-2010" TYPE="STUDY">Renders 2010</LINK>); six were of short duration (<LINK REF="STD-Kaplan_x002d_251-2001" TYPE="STUDY">Kaplan-251 2001</LINK>; <LINK REF="STD-Kasiske-1990" TYPE="STUDY">Kasiske 1990</LINK>; <LINK REF="STD-Kliem-1996" TYPE="STUDY">Kliem 1996</LINK>; <LINK REF="STD-Olbricht-1997" TYPE="STUDY">Olbricht 1997</LINK>; <LINK REF="STD-Raiola-1996" TYPE="STUDY">Raiola 1996</LINK>; <LINK REF="STD-Rigatto-1997" TYPE="STUDY">Rigatto 1997</LINK>); and one study was conducted in children (<LINK REF="STD-Gonzalez_x002d_Molina-1996" TYPE="STUDY">Gonzalez-Molina 1996</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]">
<P>Based on the current standards, the risk for bias in many of the included studies was high (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Notably however, most data for analyses were obtained from a single, large, well-conducted study in which all items of risk were low except sequence generation and allocation concealment (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>).</P>
<ALLOCATION MODIFIED="2014-01-15 13:05:18 +1100" MODIFIED_BY="[Empty name]">
<P>Random sequence generation was adequate in &lt; 25% of studies (<LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>) and allocation concealment was adequate in &lt; 25% of studies (<LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]">
<P>Participants and personnel were blinded in 50% of studies (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Arnadottir-1994" TYPE="STUDY">Arnadottir 1994</LINK>; <LINK REF="STD-Hausberg-2001" TYPE="STUDY">Hausberg 2001</LINK>; <LINK REF="STD-Kasiske-2001" TYPE="STUDY">Kasiske 2001</LINK>; <LINK REF="STD-Lepre-1999" TYPE="STUDY">Lepre 1999</LINK>; <LINK REF="STD-Sahu-2001" TYPE="STUDY">Sahu 2001</LINK>; <LINK REF="STD-Santos-2001" TYPE="STUDY">Santos 2001</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>; <LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>) while outcome assessors were blinded in &lt; 25% of studies (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>; <LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]">
<P>Completeness of outcome reporting and intention to treat analysis method was followed in &lt; 25% of included studies (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Cofan-2002" TYPE="STUDY">Cofan 2002</LINK>; <LINK REF="STD-Sahu-2001" TYPE="STUDY">Sahu 2001</LINK>; <LINK REF="STD-Sharif-2009" TYPE="STUDY">Sharif 2009</LINK>; ; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-12-19 09:28:59 +1100" MODIFIED_BY="[Empty name]">
<P>Adverse events were assessed systematically in only eight studies (36%) (<LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK>; <LINK REF="STD-Arnadottir-1994" TYPE="STUDY">Arnadottir 1994</LINK>; <LINK REF="STD-Melchor-1998" TYPE="STUDY">Melchor 1998</LINK>; <LINK REF="STD-Renders-2001" TYPE="STUDY">Renders 2001</LINK>; <LINK REF="STD-Santos-2001" TYPE="STUDY">Santos 2001</LINK>; <LINK REF="STD-Seron-2008" TYPE="STUDY">Seron 2008</LINK>; <LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_1-2005" TYPE="STUDY">UK-HARP-1 2005</LINK>).</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-04-14 08:07:48 +1000" MODIFIED_BY="Gail Y Higgins">
<SUBSECTION>
<HEADING LEVEL="3">Statin versus placebo or no treatment</HEADING>
<P>Based largely on data from a single high-quality study, statins may reduce cardiovascular mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (4 studies, 2322 participants): RR 0.68, 95% CI 0.45 to 1.01; I² = 0%); major cardiovascular events (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (1 study, 2102 participants): RR 0.84, 95% CI 0.66 to 1.06); fatal or non-fatal myocardial infarction (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (1 study, 2102 participants): RR 0.70, 95% CI 0.48 to 1.01). Overall, in absolute terms, treating 1000 adults with a functioning kidney transplant with a statin for one year may prevent two major cardiovascular events and two cardiovascular deaths (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Statin treatment had uncertain effects on all-cause mortality (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (6 studies, 2760 participants): RR 1.08, 95% CI 0.63 to 1.83; I² = 9%) and fatal or non-fatal stroke (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (1 study, 2102 participants): RR 1.18, 95% CI 0.85 to 1.63). There was no significant heterogeneity in analyses that contained more than one study.</P>
<P>Statins had uncertain effects on adverse events: creatine kinase elevation (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (3 studies, 2322 participants): RR 0.86, 95% CI 0.39 to 1.89; I² = 0%); liver enzyme elevation (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (4 studies, 608 participants): RR 0.62. 95% CI 0.33 to 1.19 I² = 0%); withdrawal due to adverse events (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK> (9 studies, 2810 participants): RR 0.89, 95% CI 0.74 to 1.06; I² = 0%); and cancer (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (1 study, 2094 participants): RR 0.94, 95% CI 0.82 to 1.07). There was no significant heterogeneity in these analyses.</P>
<P>Statins significantly reduced serum total cholesterol (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (12 studies, 3070 participants): MD -42.43 mg/dL, 95% CI -51.22 to -33.65; I² = 87%); LDL cholesterol (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> (11 studies, 3004 participants): MD -43.19 mg/dL, 95% CI -52.59 to -33.78; I² = 84%); lowered HDL cholesterol (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK> (11 studies, 3005 participants): MD -5.69 mg/dL, 95% CI -10.35 to -1.03; I² = 89%); and serum triglycerides (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK> (11 studies, 3012 participants): MD -27.28 mg/dL, 95% CI -34.29 to -20.27; I² = 15%). There was marked heterogeneity in the analyses for total cholesterol, LDL cholesterol and HDL cholesterol levels.</P>
<P>Statins had uncertain effects on kidney function: ESKD (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK> (6 studies, 2740 participants): RR 1.14, 95% CI 0.94 to 1.37; I² = 0%); acute allograft rejection (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK> (5 studies, 582 participants): RR 0.88, 95% CI 0.61 to 1.28; I² = 39%); proteinuria (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK> (2 studies, 136 participants): MD -0.04 g/24 h, 95% CI -0.17 to 0.25; I² = 0%); and GFR (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK> (1 study, 62 participants): MD -1.00 mL/min, 95% CI -9.96 to 7.96).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statin versus statin</HEADING>
<P>Due to heterogeneity in comparisons, data directly comparing differing statin regimens could not be meta-analysed.</P>
<UL>
<LI>
<LINK REF="STD-Castelao-1993" TYPE="STUDY">Castelao 1993</LINK> compared lovastatin and simvastatin head-to-head in reducing lipid parameters alone for 12 months. This study concluded that both agents had similar effects in decreasing lipid parameters (total cholesterol 193 mg/dL versus 197 mg/dL at the end of 12 months).</LI>
<LI>
<LINK REF="STD-Raiola-1998" TYPE="STUDY">Raiola 1998</LINK> compared atorvastatin 10 mg/d to fluvastatin 20 mg/d for eight weeks (30 participants) and there was significantly lower LDL cholesterol and serum triglyceride level with atorvastatin.</LI>
<LI>
<LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK> compared simvastatin 10 mg/d, pravastatin 20 mg/d and placebo among 57 kidney transplant patients. Both statins reduced lipid parameters and incidence of acute allograft rejection at a similar rate.</LI>
<LI>
<LINK REF="STD-Vergoulas-1999" TYPE="STUDY">Vergoulas 1999</LINK> compared lovastatin 20 mg/d with fluvastatin 40 mg/d among 50 kidney transplant recipients. The end of treatment total cholesterol level was lower with lovastatin than fluvastatin both at three months and one year follow-up.</LI>
<LI>In a randomised cross-over study (20 participants), simvastatin 10 mg/d was compared with simvastatin 20 mg/d (<LINK REF="STD-Celik-2000a" TYPE="STUDY">Celik 2000a</LINK>). Even though no difference was noted among the lipid parameters between these two groups, simvastatin 20 mg/d had higher occurrence of serious side effects (3) warranting drug withdrawal.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis of heterogeneity</HEADING>
<P>We found significant heterogeneity in the meta-analyses for end of study cholesterol, LDL cholesterol, HDL cholesterol and triglycerides, which we explored using pre-specified subgroup analyses.</P>
<P>For total cholesterol, statin type was the only identifiable modifier of treatment effect we found, explaining 60% of the heterogeneity. Simvastatin provided the greatest reduction in total cholesterol (5 studies, 371 participants: MD -55.57 mg/dL, 95% CI -69.17 to -41.97) and fluvastatin the least (4 studies, 2506 participants: -31.48 mg/dL, 95% CI -37.02 to -25.95). Insufficient data meant that we were unable to perform multivariate meta-regression analyses to determine the effect of dose and statin type on cholesterol levels and therefore, we were unable to determine whether differences in statin agents were due to doses used, or otherwise.</P>
<P>Dose, age of participants, proportion with diabetes, adequacy of allocation concealment, and serum cholesterol at baseline did not modify treatment effects on serum cholesterol levels. Subgroup analyses for statin type, dose, age, diabetes, allocation concealment or baseline cholesterol did not identify sources of heterogeneity for end of treatment effects of statins on LDL cholesterol or triglyceride levels. For HDL cholesterol, baseline serum cholesterol modified treatment effects of statins; in people with lower serum total cholesterol (&lt; 230 mg/dL) statins reduced HDL cholesterol (MD -15.2 mg/dL, 95% CI -20.9 to -9.6) but not in populations with higher baseline serum total cholesterol (MD -0.1 mg/dL, 95% CI -4.9 to 4.6) explaining 80% of the heterogeneity in treatment effects observed among studies.</P>
<P>Subgroup analyses for allograft rejection could not be performed due to an insufficient number of studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>Insufficient numbers of studies had data that could be included to allow formal evaluation of potential publication bias for clinical outcomes (cardiovascular events and mortality).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-01-15 13:16:33 +1100" MODIFIED_BY="Suetonia Palmer">
<P>This updated review found that in data derived largely from the well-conducted <LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK> study, statins (generally at a simvastatin dose equivalent to 10 mg/d) are likely to reduce cardiovascular events, cardiovascular death, and myocardial infarction for recipients of a kidney transplant, although the magnitude of this effect remains uncertain. While point estimates suggest the potential for benefit with statin treatment are consistent with the benefits observed in people with CKD not treated with dialysis, confidence intervals were wide and included the possibility of no effect. Statin treatment has uncertain effects on death overall and fatal or non-fatal stroke in transplant patients. The data are particularly incomplete for treatment-related harms of statins in people with a functioning kidney transplant as data are limited by lack of systematic assessment and reporting of treatment-related toxicity. Statins have uncertain effects on kidney function and transplant rejection. Statin therapy clearly reduces serum cholesterol concentrations on average by 42 mg/dL (1.1 mmol/L) as well as triglyceride concentrations, although treatment effects on cholesterol levels are inconsistent between studies. Data comparing different statins or different doses of statins were sparse in adults who have a functioning kidney transplant.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-12-19 13:45:47 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Importantly, outcome data for statins remain scant for several important clinical settings. Notably the doses of statins in the available studies were relatively low (10 mg simvastatin equivalent) and direct comparative data comparing different statin doses were sparse. Studies of higher doses or combinations of statin with other agents that lower cholesterol absorption (such as ezetimibe, as used in the recent <LINK REF="REF-SHARP-2011" TYPE="REFERENCE">SHARP 2011</LINK> study) compared to placebo are warranted, although systematic ascertainment and reporting of treatment-related toxicity in such studies would be essential. Similarly, it is also unclear whether treatment benefits from statins were dependent on reductions in serum cholesterol - as insufficient studies reporting cardiovascular and mortality outcomes also reported changes in cholesterol levels with treatment.</P>
<P>Second, sufficient data were not available to determine the relative benefits of statins in the primary prevention of cardiovascular events (treatment of individuals without clinically evident cardiovascular disease) as compared to secondary prevention (treating individuals with established cardiovascular disease) as too few studies were available to summarise data for these specific populations. It should be noted that treatment effects for mortality and cardiovascular events were consistent across all studies suggesting similar treatment effects irrespective of presence of vascular disease (although analyses for consistently were underpowered due to the small number of studies reporting events).</P>
<P>Third, data were limited by the relative paucity of available studies specifically conducted to evaluate statins in people with a functioning kidney transplant. Importantly, data for cardiovascular outcomes and mortality were almost entirely reliant on the large well-conducted <LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK> study in people with stable kidney function more than six months after kidney or combined kidney and pancreas transplantation. Studies were frequently underpowered for clinical outcomes or did not systematically ascertain outcome events, such that outcome measurement is likely to be less reliable. Additional data from further studies in transplantation would improve our confidence in the treatment estimates for statins and may change the treatment estimates observed (in other words, improve the quality of the currently available evidence).</P>
<P>One study only enrolled living-related transplant recipients (<LINK REF="STD-Sahu-2001" TYPE="STUDY">Sahu 2001</LINK>) and another only included deceased donor-related transplant recipients (<LINK REF="STD-Katznelson-1996" TYPE="STUDY">Katznelson 1996</LINK>). The remainder included mixed populations of both deceased and living donors. Of note, separate results for these different subgroups were not detailed in the reports for <LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>, <LINK REF="STD-Kasiske-2001" TYPE="STUDY">Kasiske 2001</LINK> or <LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>. Thus, whether statins have beneficial effects on these separate populations (recipients of a transplant from a deceased or living donor) could not be studied.</P>
<P>Statins have unclear effects on the development of ESKD. These data seem to mirror the uncertainty of treatment effects on kidney function we have observed with statin use in people with earlier stages of CKD not on dialysis (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>). Notably, extended follow-up of <LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK> showed no difference between statins and placebo groups for kidney outcomes, such as doubling of serum creatinine or graft loss (<LINK REF="REF-Fellstrom-2004" TYPE="REFERENCE">Fellstrom 2004</LINK>).</P>
<P>Based on the current data, the available evidence for statins is largely generalizable to people with stable kidney function who have had a kidney transplant and are at risk of cardiovascular disease. Additional data for kidney transplant recipients who have had a recent acute cardiovascular event (that is, myocardial infarction) are currently lacking, as fewer than 5% of the <LINK REF="STD-ALERT-2001" TYPE="STUDY">ALERT 2001</LINK> population had experienced a previous myocardial infarction; additional studies in this population would provide new data for this specific population.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]">
<P>Overall, outcome data were obtained from a single study at lower risk of bias. However, the vast majority of studies evaluated failed to specify whether randomisation allocation was concealed, outcome assessors were blinded or data were analysed on an intention-to-treat basis.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-12-19 13:51:39 +1100" MODIFIED_BY="Suetonia Palmer">
<P>While the review process was strengthened by being undertaken by two or more independent authors; a comprehensive search of the literature designed by a specialist librarian that included the grey literature; and the examination of all potentially relevant outcomes; potential biases exist in the review process.</P>
<P>The main weakness of this review was the relative paucity of studies available in people with a kidney transplant. The data nearly completely relies on a single large study and suggest the potential for benefit for statins on cardiovascular and mortality outcomes, but more research is needed. Reliance on a single study also reduces the generalizability of the findings to populations that have not been studied, particularly people with a functioning kidney transplant who have experienced an acute cardiovascular event. Moreover, evidence of study heterogeneity was found in some analyses, including total cholesterol, LDL cholesterol and triglycerides that could not be fully explained by prespecified subgroup analyses. Since meta-analysis assumes that a mean value estimating the effects of an intervention can be determined by combining similar studies, unexplained heterogeneity within a meta-analysis reduces the reliability of the available evidence, although it should be noted that serum total cholesterol is a surrogate outcome.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="Suetonia Palmer">
<P>In this review update, we have confirmed the findings of our earlier version of this review (<LINK REF="REF-Navaneethan-2009c" TYPE="REFERENCE">Navaneethan 2009c</LINK>) that while point estimates of treatment effect indicate statins reduce cardiovascular death and major cardiovascular events, insufficient evidence results in uncertain treatment effects that include the possibility of no benefit for people with a functioning kidney transplant. Additional evidence is particularly needed to provide high quality data for treatment-related harm. Statins have been clearly shown to reduce coronary-related mortality by approximately 20% in people with or at risk of cardiovascular disease (<LINK REF="REF-Baigent-2005" TYPE="REFERENCE">Baigent 2005</LINK>) in broader non-renal populations, and reduce mortality and major cardiovascular events by one-fifth in people with earlier stages of CKD who are not on dialysis (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>). Taking into account baseline risk of disease, treating 1000 people with cardiovascular disease or similarly treating 1000 people with CKD not on dialysis might be expected to prevent 25 to 50 deaths over five years. The results of this current review are remarkably similar to findings in the general population, suggesting that major cardiovascular events are reduced in relative terms by 16% in studies in which LDL cholesterol was lowered on average by 1.1 mmol/L, although further evidence is needed to improve our confidence in this result. Intense lipid-lowering has been associated with additional cardiovascular benefits in broader non-renal populations (<LINK REF="REF-CTT-Collaboration-2010" TYPE="REFERENCE">CTT Collaboration 2010</LINK>); a study evaluating the benefits and (particularly) harms of higher dose statins in people with a kidney transplant is now appropriate.</P>
<P>Apart from the cholesterol lowering effects, statins are known to have anti-inflammatory, anti-proliferative and immunosuppressive effects (<LINK REF="REF-Corsini-1993" TYPE="REFERENCE">Corsini 1993</LINK>; <LINK REF="REF-Kurakata-1996" TYPE="REFERENCE">Kurakata 1996</LINK>). These pleiotropic effects noted by in-vitro studies suggested their possible impact on acute allograft rejection (<LINK REF="REF-Massy-1996" TYPE="REFERENCE">Massy 1996</LINK>). Earlier, observational studies have indicated a possible role for statins in decreasing allograft rejection and two studies have shown that statins significantly reduced acute allograft rejection rates (<LINK REF="STD-Kasiske-2001" TYPE="STUDY">Kasiske 2001</LINK>; <LINK REF="STD-Tuncer-2000" TYPE="STUDY">Tuncer 2000</LINK>) but other studies have not confirmed this finding (<LINK REF="STD-SOLAR-Study-2001" TYPE="STUDY">SOLAR Study 2001</LINK>; <LINK REF="STD-Renders-2001" TYPE="STUDY">Renders 2001</LINK>; <LINK REF="STD-Sahu-2001" TYPE="STUDY">Sahu 2001</LINK>). A meta-analysis of the role of statins in heart transplant recipients has concluded that statins decrease allograft rejection episodes and improve one year heart transplant survival (<LINK REF="REF-Mehra-2004" TYPE="REFERENCE">Mehra 2004</LINK>), findings which at present cannot be confirmed by this review of studies conducted in kidney transplant recipients.</P>
<P>The NKF-DOQI guidelines recommend initiating low dose statins in kidney transplant recipients when LDL cholesterol is above 100 mg/dL in addition to therapeutic lifestyle changes (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) (<LINK REF="REF-Kasiske-2004" TYPE="REFERENCE">Kasiske 2004</LINK>). The European Best Practice guidelines currently recommend initiating statins when LDL cholesterol is above 130 mg/dL (<LINK REF="REF-EBPG-2002" TYPE="REFERENCE">EBPG 2002</LINK>). Recently released Kidney Disease Improving Global Outcomes guidelines also recommend lowering LDL cholesterol levels to below 100 mg/dL and endorse the NKF-DOQI guidelines recommendations (<LINK REF="REF-KDIGO-2009" TYPE="REFERENCE">KDIGO 2009</LINK>). Our analysis has shown the use of statins decrease LDL by an average of 45 mg/dL (1.1 mmol/L) and their use may be supported by these surrogate outcomes. We were not able to evaluate whether treatment effects of statins on cardiovascular and mortality outcomes were dependent on cholesterol lowering; recent data in the general population showing benefits for statins even in people with LDL cholesterol levels below 130 mg/dL (3.4 mmol/L, <LINK REF="REF-JUPITER-2008" TYPE="REFERENCE">JUPITER 2008</LINK>) suggest cholesterol targets in people who have a kidney transplant may not be necessary. A similar study evaluating effects of statins in kidney transplant recipients irrespective of serum cholesterol levels may be warranted.</P>
<P>A previously published systematic review, which looked at the impact of statins in kidney transplant recipients, concluded that statins reduced lipid parameters significantly without any reduction in allograft rejection rates (<LINK REF="REF-Lentine-2004" TYPE="REFERENCE">Lentine 2004</LINK>); our review confirms these findings.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-12-19 13:57:30 +1100" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2013-12-18 16:13:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Currently, statin therapy may reduce major cardiovascular events and cardiovascular mortality in kidney transplant recipients, although future research is needed to increase our confidence in this finding. Adverse events from treatment are incompletely understood and need to be considered when deciding on statin use in this population. Statin therapy clearly reduces serum cholesterol levels but has uncertain effects on kidney function and risks of acute rejection. Data are particularly sparse for people who have a kidney transplant who have experienced an acute cardiovascular event. Doses used in available studies are relatively low (simvastatin 10 mg equivalent); the benefits and harms of more intensive therapy are less known.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-12-19 13:57:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>In light of the widespread adoption of statins, additional research is still needed to improve our confidence in the potential benefits and harms of statin therapy in kidney transplant recipients (where data are currently sparse). Additional studies in transplant populations that evaluate cardiovascular and mortality outcomes with more intensive lipid lowering together with systematic ascertainment and reporting of adverse treatment toxicity are required. Randomised data for primary and secondary prevention of cardiovascular disease in the transplant setting would be informative. In addition, post-marketing surveillance would provide additional important data about treatment harms of statins in this population. Studies that include people with a kidney transplant irrespective of baseline serum total cholesterol would be relevant. Since performing large studies is difficult and costly to individual centres, a trialists&#8217; consortium may assist with infrastructure, recruitment and follow-up of statin studies in kidney transplant recipients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-19 13:58:22 +1100" MODIFIED_BY="[Empty name]">
<P>We acknowledge the contribution of authors (Drs Holdaas and Baigent) who provided data about their studies upon request. We also thank Narelle Willis, for her help in coordinating and editing this review and Ruth Mitchell and Gail Higgins for assistance in the development of the search strategies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-12-19 13:58:57 +1100" MODIFIED_BY="Narelle S Willis">
<P>David Johnson is a consultant for Baxter Healthcare Pty Ltd and has previously received research funds from this company. He has also received speakers&#8217; honoraria and research grants from Fresenius Medical Care and is a current recipient of a Queensland Government Health Research Fellowship. He has also received speakers' honoraria and consultancy fees from Amgen, Janssen-Cilag, Shire, Lilley, Boehringer-Ingelheim and Merck Sharpe &amp; Dohme. He has received a research grant from Pfizer.</P>
<P>Suetonia Palmer received a fellowship administered by the Consorzio Mario Negri Sud from Amgen Dompe for assistance with travel for collaboration and supervision.</P>
<P>Vlado Perkovic is supported by a fellowship from the Heart Foundation of Australia and a various grants from the Australian National Health and Medical Research Council. He has received speakers' fees from Roche, Servier and Astra Zeneca, funding for a clinical trial from Baxter, and serves on Steering Committees for trials funded by Johnson and Johnson, Boehringer Ingelheim, Vitae and Abbott. His employer conducts clinical trials funded by Servier, Johnson and Johnson, Roche and Merck.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-12-19 14:00:45 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Suetonia Palmer: data extraction, analysis and interpretation of data, drafting the manuscript, final approval of version to be published</LI>
<LI>Sankar D Navaneethan: concept and design of the review, data extraction, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
<LI>Sagar Nigwekar: data extraction, analysis and interpretation of data, writing the final manuscript</LI>
<LI>Vlado Perkovic: critical revision for intellectual content, interpretation of data, assistance with writing of the final manuscript, final approval of the manuscript to be submitted for publication</LI>
<LI>David W Johnson: data extraction, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
<LI>Jonathan Craig: concept and design, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
<LI>Giovanni FM Strippoli: concept and design of the review, data extraction, analysis and interpretation of data, writing the final manuscript, final approval of version to be published.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-03-12 13:21:08 +1100" MODIFIED_BY="Narelle S Willis">
<P>Risk of bias assessment tool has replaced the earlier quality assessment checklist (<LINK REF="REF-Perkovic-2004" TYPE="REFERENCE">Perkovic 2004</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-10-08 14:10:43 +1100" MODIFIED_BY="Gail Y Higgins">
<STUDIES MODIFIED="2014-10-08 14:10:43 +1100" MODIFIED_BY="Gail Y Higgins">
<INCLUDED_STUDIES MODIFIED="2014-04-14 08:07:48 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDY DATA_SOURCE="PUB" ID="STD-ALERT-2001" MODIFIED="2014-01-15 14:06:13 +1100" MODIFIED_BY="Gail Y Higgins" NAME="ALERT 2001" YEAR="2003">
<REFERENCE MODIFIED="2012-01-31 14:59:56 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abedini S, Holme I, Fellstrom B, Jardine A, Cole E, Maes B, et al</AU>
<TI>Cerebrovascular events in renal transplant recipients</TI>
<SO>Transplantation</SO>
<YR>2009</YR>
<VL>87</VL>
<NO>1</NO>
<PG>112-7</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:59:54 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19136900"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:59:47 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abedini S, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A, et al</AU>
<TI>Inflammation in renal transplantation</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>7</NO>
<PG>1246-54</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:58:51 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19541816"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:41:19 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abedini S, Jardine A, Fellstrom B, Holdaas H</AU>
<TI>Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>Suppl 2</NO>
<PG>207</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:41:19 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:41:19 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00763910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:42:10 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abedini S, Jardine A, Fellstrom B, Meinitzer A, Marz W, Bermann G, et al</AU>
<TI>Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F-FC149]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>68A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:42:10 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:42:10 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00689307"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:58:38 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abedini S, Meinitzer A, Holme I, Marz W, Weihrauch G, Fellstrom B, et al</AU>
<TI>Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients</TI>
<SO>Kidney International</SO>
<YR>2010</YR>
<VL>77</VL>
<NO>1</NO>
<PG>44-50</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:58:36 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19847152"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-20 09:30:59 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C, et al</AU>
<TI>No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study</TI>
<SO>Clinical Transplantation</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>6</NO>
<PG>732-9</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:30:09 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17100723"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:58:24 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine A, Cole E, Nyberg G, Grohagen-Riska C, et al</AU>
<TI>Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation - experience from the ALERT trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>187A</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:58:24 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:58:14 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Effects of fluvastatin on graft losses and renal function in renal transplantation - experience from the ALERT trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>10A</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:58:14 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:58:18 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Risk factors for graft loss or doubling of serum creatinine in renal transplantation - experience from the ALERT trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>185A</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:58:18 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:43:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine A, Holme I, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>236</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:43:24 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-15 13:43:24 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00445309"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-27 15:31:49 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, et al</AU>
<TI>Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>4</NO>
<PG>1549-55</PG>
<IDENTIFIERS MODIFIED="2013-11-27 15:31:49 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-11-27 15:31:49 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15458450"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-19 11:37:02 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al</AU>
<TI>Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial</TI>
<SO>Transplantation</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2</NO>
<PG>205-12</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:36:48 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15665769"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:44:15 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdass H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation - experience from the ALERT trial [abstract]</TI>
<SO>Transplantation</SO>
<YR>2004</YR>
<VL>78</VL>
<NO>2 Suppl</NO>
<PG>57</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:44:15 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:44:15 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00509185"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-19 11:24:50 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Jardine AG, Soveri I, Cole E, Gronhagen-Riska C, Neumayer HH, et al</AU>
<TI>Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial</TI>
<SO>Transplantation</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>9</NO>
<PG>1160-3</PG>
<IDENTIFIERS MODIFIED="2013-12-19 11:24:48 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-12-19 11:24:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15880062"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-21 15:49:24 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, et al</AU>
<TI>Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation</TI>
<SO>American Journal of Transplantation</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>8</NO>
<PG>1986-91</PG>
<IDENTIFIERS MODIFIED="2010-12-21 15:49:20 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15996249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:46:38 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom BC, Holdaas H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>Suppl 8</NO>
<PG>261</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:46:38 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:46:38 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00509187"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:47:55 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Abedini S, Jardine A, Maes B, März W, Fellstrom B</AU>
<TI>Parathyroid hormone and phosphate - risk factors for post-transplant cardiovascular disease? [abstract no: TH-FC084]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>19A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:47:55 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:47:55 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00615900"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:48:51 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Asberg A, Edvardsen C, Hartmann A</AU>
<TI>Statins endothelial function in renal transplant recipients - a randomised single centre study [abstract no: A4677]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>894A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:48:40 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 13:48:40 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00776306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-20 09:31:26 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al</AU>
<TI>Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study</TI>
<SO>American Journal of Transplantation</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>12</NO>
<PG>2929-36</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:41:07 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16303007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-27 15:20:52 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Holme I, Nyberg G, Fauchald P, Jardine A, et al</AU>
<TI>Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data</TI>
<SO>Journal of Cardiovascular Risk</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>2</NO>
<PG>63-71</PG>
<IDENTIFIERS MODIFIED="2013-11-27 15:20:52 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-11-27 15:20:52 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11324372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:49:42 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardin A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract no: M-PO50032]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A88</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:49:42 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:49:42 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00615876"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:50:59 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Cole E, Maes B, Nyberg G, et al</AU>
<TI>Risk factors for late new-onset diabetes mellitus after renal transplantation [abstract no: 675]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>Suppl 11</NO>
<PG>328</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:50:59 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:50:59 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00757934"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:51:46 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Lipid-lowering therapy should be started early in the post-transplant period [abstract no: F-PO569]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>185A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:51:46 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:51:46 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550528"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:52:32 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract no: SO01]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v3</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:52:32 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:52:32 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00601991"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:53:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Gimpelewicz C, Staffler B, Logan J, et al</AU>
<TI>No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>881A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:53:24 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:53:24 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550529"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:54:06 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Gimpelewicz C, Staffler B, Logan J, et al</AU>
<TI>Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA-PO1048]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>527A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:54:06 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:54:06 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550531"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:54:45 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Holme I, Nyberg G, Fauchald P, et al</AU>
<TI>Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>Suppl 5</NO>
<PG>442</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:54:45 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:54:45 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00445757"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:55:27 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Holme I, Nyberg G, et al</AU>
<TI>Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>237</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:55:27 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:55:27 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00445756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-03 16:47:27 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Nyberg G, Gronhagen-Riska C, Madsen S, et al</AU>
<TI>Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>72A</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:51:42 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:57:09 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine A, Nyberg G, Gronhagen-Riska C, Madsen S, et al</AU>
<TI>No detrimental effect on renal function during long-term use of fluvastatin [abstract]</TI>
<SO>Transplantation</SO>
<YR>2004</YR>
<VL>78</VL>
<NO>2 Suppl</NO>
<PG>327</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:57:09 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:57:09 +1100" MODIFIED_BY="Narelle Willis" TYPE="OTHER" VALUE="CN-00509236"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:57:55 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine AG, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Lipids as risk factors for cardiac events after renal transplantation - experience from the ALERT trial [abstract no: SU-PO590]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>662A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:57:55 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:57:55 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550542"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-20 09:31:54 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al</AU>
<TI>Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9374</NO>
<PG>2024-31</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:22:22 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 11:22:22 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="12814712"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-20 09:32:08 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al</AU>
<TI>Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>5</NO>
<PG>974-80</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:54:20 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15784644"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:58:52 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Maes B, Cole E, Jardine A</AU>
<TI>Impact of hemoglobin levels on graft function, cardiac events and all-cause mortality after renal transplantation [abstract no: F-PO1502]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>443A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 13:58:52 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:58:52 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00756929"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:59:33 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Holdaas H, Jardine A, Holme I, Brekke IB, Wheeler DC, Ostraat O, et al</AU>
<TI>A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]</TI>
<SO>XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy)</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2014-01-15 13:59:33 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 13:59:33 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00527128"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:16:19 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<AU>Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, et al</AU>
<TI>Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>5</NO>
<PG>1990-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21561172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:56:57 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holme I, Fellstrom B, Jardine A, Holdaas H</AU>
<TI>Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients</TI>
<SO>Atherosclerosis</SO>
<YR>2010</YR>
<VL>208</VL>
<NO>1</NO>
<PG>234-9</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:56:54 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19596331"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:00:26 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine A, Weihrauch G, Maerz W, Fellstrom B, Bermann G, Holdaas H</AU>
<TI>Osteoprotegerin - a novel risk factor post-transplant cardiovascular disease [abstract no: TH-PO581]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>231A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:00:26 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:00:26 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00615825"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:01:29 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine AG, Fellstrom B, Cole E, Logan J, Holdaas H</AU>
<TI>New targets for cardiovascular risk reduction in renal transplant recipients: post-hoc analyses of the ALERT study [abstract no: SU-PO991]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>746A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:01:29 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:01:29 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550611"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-19 11:57:12 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>3</NO>
<PG>529-36</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:57:09 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16129216"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-20 09:32:23 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>6</NO>
<PG>988-95</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:57:25 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15147434"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:02:35 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, et al</AU>
<TI>Pulse pressure and outcomes following renal transplantation [abstract no: SU-FC294]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>64A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:02:26 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:02:26 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00724902"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:03:09 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine AG, Holdaas H, Fellstrom B, the ALERT Investigators</AU>
<TI>Adverse impact of steroids on outcome in the ALERT study [abstract]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>Suppl 8</NO>
<PG>488</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:03:09 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:03:09 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00509253"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:04:01 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norby G, Soveri I, Fellstrom B, Jardine A, Cole E, Maerz W, et al</AU>
<TI>C-Reactive protein (CRP) and interleukin-6 (IL-6) are associated with long-term renal and cardiac outcomes in renal transplant recipients [abstract no: SA-PO446]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>438A-9A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:03:52 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:03:52 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00716046"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:56:19 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norby GE, Holme I, Fellstrom B, Jardine A, Cole E, Abedini S, et al</AU>
<TI>Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2009</YR>
<VL>60</VL>
<NO>4</NO>
<PG>1060-4</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:56:17 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19333947"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-20 09:32:29 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oien CM, Reisaeter AV, Os I, Jardine A, Fellstrom B, Holdaas H</AU>
<TI>Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study</TI>
<SO>Clinical Transplantation</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>374-82</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:58:43 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16824157"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-19 11:58:59 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, et al</AU>
<TI>Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients</TI>
<SO>Journal of Lipid Research</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>9</NO>
<PG>2072-8</PG>
<IDENTIFIERS MODIFIED="2009-01-19 11:58:54 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="17563401"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 14:56:07 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellstrom B</AU>
<TI>Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment</TI>
<SO>Clinical Transplantation</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>6</NO>
<PG>914-20</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:56:05 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19594771"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:05:15 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soveri I, Holdaas H, Jardine A, Eriksson N, Fellstrom B</AU>
<TI>Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]</TI>
<SO>Transplantation</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>2S</NO>
<PG>212</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:05:15 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:05:15 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00757239"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:06:13 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soveri I, Holdaas H, Jardine A, Eriksson N, Fellstrom B</AU>
<TI>Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]</TI>
<SO>Transplantation</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>2S</NO>
<PG>43</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:06:13 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:06:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00757241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnadottir-1994" MODIFIED="2013-12-05 18:26:51 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Arnadottir 1994" YEAR="1993">
<REFERENCE MODIFIED="2013-12-05 18:26:51 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arnadottir M, Eriksson LO, Germershausen JI, Thysell H</AU>
<TI>Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients</TI>
<SO>Nephron</SO>
<YR>1994</YR>
<VL>68</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS MODIFIED="2013-12-05 18:26:51 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-12-05 18:26:51 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="7991041"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bill-1995" MODIFIED="2014-01-15 14:09:37 +1100" MODIFIED_BY="[Empty name]" NAME="Bill 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-01-15 14:07:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bill M, Paczek L, Gaciong Z, Gradowska L, Lao M, Wyzgal J, et al</AU>
<TI>Low dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>1061</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:07:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-15 14:07:46 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00261145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-31 15:01:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bill M, Paczek L, Wyzgal J, Baciong Z, Gradowska L, Lao M, Juskowa J, et al</AU>
<TI>Six-month treatment with low-dose lovastatin does not improve kidney allograft function</TI>
<SO>Polish Journal of Immunology</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>4</NO>
<PG>417-9</PG>
<IDENTIFIERS MODIFIED="2012-01-31 15:01:20 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-03 13:45:55 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paczek L, Bill M, Wyzgal J, Gaciong Z, Gradowska L, Juskowa J, et al</AU>
<TI>The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers</TI>
<SO>Polskie Archiwum Medycyny Wewnetznej</SO>
<YR>1997</YR>
<VL>97</VL>
<NO>2</NO>
<PG>144-56</PG>
<IDENTIFIERS MODIFIED="2009-02-03 11:35:44 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-03 11:35:44 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9312763"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-27 16:38:40 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paczek L, Bill M. Wyzgal J, Gradowska L, Galazka Z, Gaciong Z</AU>
<TI>Non-immune factors in chronic rejection. Is there a role for hypolipemic drugs?</TI>
<SO>Annals of Transplantation</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>2</NO>
<PG>65-9</PG>
<IDENTIFIERS MODIFIED="2013-11-27 16:38:39 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-27 16:38:39 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9869855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:09:37 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paczek L, Gradowska L, Bill M, Gaciong Z, Lao M, Juskowa J, et al</AU>
<TI>Treatment with low-dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S574</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:09:37 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-15 14:09:37 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00461456"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castelao-1993" MODIFIED="2012-03-06 08:52:46 +1100" MODIFIED_BY="[Empty name]" NAME="Castelao 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-06 08:52:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Castelao AM, Grino JM, Andres E, Gilvernet S, Seron D, Castineiras MJ, et al</AU>
<TI>HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>1 Pt 2</NO>
<PG>1043-6</PG>
<IDENTIFIERS MODIFIED="2009-02-02 12:21:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 12:21:13 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8442035"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:12:07 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Castelao A, Grinyo JM, Gil-Vernet S, Seron D, Castineiras MJ, Ramos R, et al</AU>
<TI>Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression</TI>
<SO>Transplantation Proceedings</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>1</NO>
<PG>398-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11959343"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celik-2000a" MODIFIED="2014-04-14 08:07:48 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Celik 2000a" YEAR="2000">
<REFERENCE MODIFIED="2012-03-06 08:52:53 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Celik A, Unsal A, Mutaf I, Habif S, Ok E, Bayindir O</AU>
<TI>Which dosage of simvastatin in renal transplant patients?</TI>
<SO>Nephron</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>1</NO>
<PG>81-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10644914"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cofan-2002" MODIFIED="2009-02-02 12:22:46 +1100" MODIFIED_BY="[Empty name]" NAME="Cofan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-19 10:40:54 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cofan F, Gilabert R, Zambon D, Nunez I, Ros E, Cofan M, et al</AU>
<TI>Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients</TI>
<SO>Transplantation Proceedings</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>1</NO>
<PG>384-8</PG>
<IDENTIFIERS MODIFIED="2009-01-19 10:40:19 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 10:40:18 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="11959338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-02 12:22:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cofan F, Zambon D, Laguna JC, Casals E, Ros E, Cofan M, et al</AU>
<TI>Pravastatin improves low-density lipoprotein oxidation in renal transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>2</NO>
<PG>389-91</PG>
<IDENTIFIERS MODIFIED="2009-01-19 10:39:31 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 10:39:31 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="11959339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hausberg-2001" MODIFIED="2014-01-15 14:10:47 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Hausberg 2001" YEAR="2001 Apr">
<REFERENCE MODIFIED="2014-01-15 14:10:15 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hausberg M, Barenbrock M, Stam F, Kosch M, Kisters K, Heidenreich S, et al</AU>
<TI>Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>677A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:10:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:10:15 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00445668"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:10:47 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hausberg M, Barenbrock M, Stam F, Kosch M, Kisters K, Spieker C, et al</AU>
<TI>HMG-CoA-reductase inhibitors improve brachial artery flow-mediated vasodilation in renal transplant recipients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A282</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:10:47 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:10:47 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00484274"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-06 08:53:08 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hausberg M, Kosch M, Stam F, Heidenreich S, Kisters K, Rahn KH, et al</AU>
<TI>Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>59</VL>
<NO>4</NO>
<PG>1473-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11260410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:16:40 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosch M, Barenbrock M, Hausberg M</AU>
<TI>Sustained beneficial effect of a therapy with the HMG-Co-A-reductase inhibitor fluvastatin on endothelial function in renal transplant recipients</TI>
<SO>Nieren-und Hochdruckkrankheiten</SO>
<YR>2004</YR>
<VL>33</VL>
<NO>10</NO>
<PG>577-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="2004495206"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:16:40 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M</AU>
<TI>Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>5</NO>
<PG>1088-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12722044"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasiske-2001" MODIFIED="2014-01-15 14:12:15 +1100" MODIFIED_BY="[Empty name]" NAME="Kasiske 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-05 18:30:37 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B</AU>
<TI>The effects of lipid-lowering agents on acute renal allograft rejection</TI>
<SO>Transplantation</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>2</NO>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2013-12-05 18:30:37 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-12-05 18:30:37 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11477342"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:12:15 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ</AU>
<TI>Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]</TI>
<SO>Transplantation</SO>
<YR>2000</YR>
<VL>69</VL>
<NO>8 Suppl</NO>
<PG>S225</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:12:15 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:12:15 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00446023"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katznelson-1996" MODIFIED="2014-01-15 14:12:48 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Katznelson 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-01-15 14:12:48 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katznelson S, Wilkinson AH, Danovitch GM, Wang XM, Chia D, Kobashigawa JA, et al</AU>
<TI>Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>1017</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:12:48 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:12:48 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00601908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-07 15:03:26 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Katznelson S, Wilkinson AH, Danovitch GM, Wang XM, Chia D, Ozawa M, et al</AU>
<TI>The impact of pravastatin on the incidence of acute rejection after renal transplantation and on cellular immune function [abstract]</TI>
<SO>14th Annual Meeting American Society of Transplant Physicians (ASTP);1995 May 10-14; Chicago (USA)</SO>
<YR>1995</YR>
<IDENTIFIERS MODIFIED="2011-12-19 14:21:03 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-05 18:48:03 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al</AU>
<TI>The effect of pravastatin on acute rejection after kidney transplantation--a pilot study</TI>
<SO>Transplantation</SO>
<YR>1996</YR>
<VL>61</VL>
<NO>10</NO>
<PG>1469-74</PG>
<IDENTIFIERS MODIFIED="2013-12-05 18:48:03 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-12-05 18:48:03 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8633373"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepre-1999" MODIFIED="2013-12-05 18:50:57 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Lepre 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-05 18:50:57 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lepre F, Rigby R, Hawley C, Saltissi D, Brown A, Walsh Z</AU>
<TI>A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients</TI>
<SO>Clinical Transplantation</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>6</NO>
<PG>520-5</PG>
<IDENTIFIERS MODIFIED="2013-12-05 18:50:57 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-12-05 18:50:57 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10617243"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-Hernandez-1993" MODIFIED="2014-01-15 14:15:26 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Martinez Hernandez 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-12-05 18:53:15 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF</AU>
<TI>Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>7</NO>
<PG>637-41</PG>
<IDENTIFIERS MODIFIED="2013-12-05 18:53:15 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-12-05 18:53:15 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="8396749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:15:26 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Hernandez B, Persaud JW, Varghese Z, Moorhead JF</AU>
<TI>Low dose simvastatin (LS) is safe in hyperlipidemic transplant patients treated with CyA [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>869</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:15:26 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:15:26 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00461259"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melchor-1998" MODIFIED="2012-03-06 08:53:31 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Melchor 1998" YEAR="1998 Aug">
<REFERENCE MODIFIED="2012-03-06 08:53:31 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Melchor JL, Gracida C</AU>
<TI>Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients</TI>
<SO>Transplantation Proceedings</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>5</NO>
<PG>2054</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9723390"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raiola-1998" MODIFIED="2014-01-15 14:16:02 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Raiola 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-01-15 14:16:02 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raiola P, Manzo M, Saggese A</AU>
<TI>Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>693A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:16:02 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:16:02 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00447330"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renders-2001" MODIFIED="2014-01-15 14:16:42 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Renders 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-01-15 14:16:42 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renders L, Mayer-Kadner I, Koch C, Burkhardt K, Veelken R, Schmieder R, et al</AU>
<TI>Cerivastatin and atorvastatin: efficacy, safety and drug-interaction of the new HMG-COA reductase inhibitors in renal transplant patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>694A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:16:42 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:16:42 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00447381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-06 08:53:49 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Renders L, Mayer-Kadner I, Koch C</AU>
<TI>Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>1</NO>
<PG>141-6</PG>
<IDENTIFIERS MODIFIED="2009-02-03 14:06:05 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-03 14:06:05 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11209008"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahu-2001" MODIFIED="2014-01-15 14:17:26 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Sahu 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-03-06 08:54:02 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sahu K, Sharma R, Gupta A</AU>
<TI>Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection</TI>
<SO>Clinical Transplantation</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>173-5</PG>
<IDENTIFIERS MODIFIED="2009-01-19 14:16:54 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 14:16:54 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="11389707"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:17:26 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma RK, Sahu KM, Gupta A, Gulati S, Agarwal DK, Kumar A, et al</AU>
<TI>Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A288</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:17:26 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:17:26 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00485837"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-2001" MODIFIED="2014-01-15 14:24:22 +1100" MODIFIED_BY="Narelle S Willis" NAME="Santos 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-01-15 14:18:14 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Garcia V, Bittar A, Keitel E, Neumann J, Saitovitch D, Santos A</AU>
<TI>Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441]</TI>
<SO>A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey)</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2014-01-15 14:18:14 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:18:14 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00671773"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:20:07 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Garcia V, Bittar A, Keitel E, Neumann J, Saitovitch D, Santos A</AU>
<TI>Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind, randomized placebo controlled study [abstract no: 1439]</TI>
<SO>A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey)</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2014-01-15 14:20:07 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:20:07 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00615908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:22:52 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Santos AF, Keitel E, Bittar A, Neumann J, Saitovich D, Seelig DC, et al</AU>
<TI>Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311]</TI>
<SO>XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL)</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2014-01-15 14:22:48 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:22:48 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00416585"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:22:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Santos AF, Keitel E, Bittar A, Neumann J, Saitovich D, Seelig DC, et al</AU>
<TI>Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind randomized placebo controlled study [abstract no:3367]</TI>
<SO>XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL)</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2014-01-15 14:22:05 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:22:05 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00416586"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:14:04 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos AF, Keitel E, Bittar AE, Neumann J, Fonseca N, Sporleder H, et al</AU>
<TI>Simvastatin effect on NK cells activity in vivo: a double-blind randomized, placebo-controlled study</TI>
<SO>Transplantation Proceedings</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>7</NO>
<PG>2874-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12431639"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-19 14:41:11 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Santos AF, Keitel E, Bittar AE, Neumann J, Fuchs FD, Goldani JC, et al</AU>
<TI>Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study</TI>
<SO>Transplantation Proceedings</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>1-2</NO>
<PG>1194-5</PG>
<IDENTIFIERS MODIFIED="2009-01-19 14:41:07 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11267254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:24:22 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Santos AF, Keitel E, Bittar AE, Neumann J</AU>
<TI>Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double-blind, randomized, placebo-controlled study [abstract no: PO601]</TI>
<SO>XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy)</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2014-01-15 14:24:22 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:24:22 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00465849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seron-2008" MODIFIED="2012-03-06 08:54:15 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Seron 2008" YEAR="2008 Jul 15">
<REFERENCE MODIFIED="2012-03-06 08:54:15 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seron D, Oppenheimer F, Pallardo LM, Lauzurica R, Errasti P, Gomez-Huertas E, et al</AU>
<TI>Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial</TI>
<SO>Transplantation</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>1</NO>
<PG>82-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18622282"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharif-2009" MODIFIED="2014-01-15 14:26:49 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Sharif 2009" YEAR="2009 Jun">
<REFERENCE MODIFIED="2014-01-15 14:25:17 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharif A, Ravindran V, Moore R, Baboolal K</AU>
<TI>The effects of rosuvastatin on 51CR-EDTA measured glomerular filtration rate and urinary albumin excretion in non-diabetic renal transplant recipients [abstract no: 1386]</TI>
<SO>Transplantation</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>2S</NO>
<PG>466</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:25:17 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:25:17 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00766701"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-06 08:54:24 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharif A, Ravindran V, Moore R, Dunseath G, Luzio S, Owens D, et al</AU>
<TI>The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients</TI>
<SO>American Journal of Transplantation</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1439-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19459810"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:26:08 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharif A, Ravindran V, Moore R, Dunseath G, Luzio S, Owens D, et al</AU>
<TI>The effects of rosuvastatin on insulin sensitivity and secretion in non-diabetic renal transplant recipients [abstract no: 611]</TI>
<SO>Transplantation</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>2S</NO>
<PG>214</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:26:08 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:26:08 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00766702"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:26:49 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharif A, Ravindran V, Moore R, Luzio S, Dunseath G, Owens D, et al</AU>
<TI>Influence of rosuvastatin on attenuation of the metabolic syndrome in non-diabetic renal transplant recipients [abstract no: 60]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>Suppl 2</NO>
<PG>208</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:26:49 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:26:49 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00775209"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:14:27 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharif A, Ravindran V, Moore R, Luzio S, Dunseath G, Owens D, et al</AU>
<TI>Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients</TI>
<SO>Journal of Diabetes</SO>
<YR>2009</YR>
<VL>1</VL>
<PG>A92-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="70212602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SOLAR-Study-2001" MODIFIED="2014-01-15 14:28:10 +1100" MODIFIED_BY="Suetonia Palmer" NAME="SOLAR Study 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-18 09:58:11 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A</AU>
<TI>Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation</TI>
<SO>Clinical Transplantation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>4</NO>
<PG>385-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12868997"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:27:25 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Jardine A, Holme I, SOLAR Study Group</AU>
<TI>The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A319</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:27:25 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:27:25 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00484378"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:28:10 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Holdaas H, Jardine A, Wheeler D</AU>
<TI>Fluvastatin (lescol) demonstrates significant lipid-lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]</TI>
<SO>A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey)</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2014-01-15 14:28:07 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:28:07 +1100" MODIFIED_BY="Narelle Willis" TYPE="OTHER" VALUE="CN-00445759"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, et al</AU>
<TI>Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>5</NO>
<PG>1990-7</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:57:55 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 09:57:55 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11703619"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuncer-2000" MODIFIED="2012-03-06 08:54:48 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Tuncer 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-06 08:54:48 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G</AU>
<TI>Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients</TI>
<SO>Transplantation Proceedings</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>3</NO>
<PG>622-5</PG>
<IDENTIFIERS MODIFIED="2009-01-19 14:46:33 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 14:46:33 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="10812143"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK_x002d_HARP_x002d_1-2005" MODIFIED="2014-01-15 14:29:05 +1100" MODIFIED_BY="Gail Y Higgins" NAME="UK-HARP-1 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-19 10:44:02 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al</AU>
<TI>First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>3</NO>
<PG>473-84</PG>
<IDENTIFIERS MODIFIED="2009-01-19 10:43:55 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 10:43:55 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15754269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:29:05 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, UK-HARP Steering Committee</AU>
<TI>Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>Program &amp; Abstracts</NO>
<PG>437a</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:29:05 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2014-01-15 14:29:05 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00444305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vergoulas-1999" MODIFIED="2014-01-15 14:30:04 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Vergoulas 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-01-15 14:30:04 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vergoulas G, Miserlis G, Gakis D, Imvrios G, Papagiannis A, Papanikolaou V, et al</AU>
<TI>Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A312</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:30:04 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:30:04 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00486302"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-10-08 14:10:43 +1100" MODIFIED_BY="Gail Y Higgins">
<STUDY DATA_SOURCE="PUB" ID="STD-Bagdade-1979" MODIFIED="2011-10-23 14:07:17 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Bagdade 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-10-23 14:07:17 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bagdade JD, Shantharam VV, Sollek M, Albers JJ</AU>
<TI>Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients</TI>
<SO>Clinical Nephrology</SO>
<YR>1979</YR>
<VL>12</VL>
<NO>2</NO>
<PG>83-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="230927"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blechman_x002d_Krom-2000" MODIFIED="2013-12-19 11:00:57 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Blechman-Krom 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-19 11:00:57 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<AU>Blechman-Krom I</AU>
<TI>An interventional trial in established chronic renal allograft rejection</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00005010</SO>
<YR>(accessed 19 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00005010"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-2000" MODIFIED="2014-01-15 14:31:11 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Blum 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-01-15 14:31:11 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum CB, Rapamune US Study Group</AU>
<TI>Cholesterol and triglyceride levels in sirolimus-treated renal transplant recipients [abstract no: A3577]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>680A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:31:11 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:31:11 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550429"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capone-1999" MODIFIED="2011-10-23 14:07:46 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Capone 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-10-23 14:07:46 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V</AU>
<TI>Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients</TI>
<SO>American Journal of Nephrology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>3</NO>
<PG>411-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10393380"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-1997" MODIFIED="2011-10-28 18:48:48 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Castro 1997" YEAR="1997 Oct">
<REFERENCE MODIFIED="2011-10-28 18:48:48 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmento AM, et al</AU>
<TI>Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>10</NO>
<PG>2140-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9351079"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1995" MODIFIED="2014-01-15 14:31:51 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Cheng 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-01-15 14:31:51 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cheng IKP, Li PWC, Janus ED, Tang CSO, Chan TM, Lo CY</AU>
<TI>Comparative efficacy of gemfibrozil (G) and simvastatin (S) in the treatment of hyperlipidaemia in renal transplant recipients (RT) - a randomised prospective study [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)</SO>
<YR>1995</YR>
<PG>383</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:31:51 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:31:51 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00509131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curtis-1982" MODIFIED="2011-10-23 14:08:24 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Curtis 1982" YEAR="1982 Jul">
<REFERENCE MODIFIED="2011-10-23 14:08:24 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG</AU>
<TI>Effect of alternate-day prednisone on plasma lipids in renal transplant recipients</TI>
<SO>Kidney International</SO>
<YR>1982</YR>
<VL>22</VL>
<NO>1</NO>
<PG>42-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6750206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_de_x002d_la_x002d_Puente-2009" MODIFIED="2013-11-27 15:04:56 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Garcia-de-la-Puente 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-10-23 14:08:34 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, Bojorquez-Ochoa A, Maya ER, Perez-Martinez MP</AU>
<TI>Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders</TI>
<SO>Pediatric Nephrology</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>6</NO>
<PG>1205-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19238452"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez_x002d_Molina-1996" MODIFIED="2014-01-15 14:32:45 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Gonzalez-Molina 1996" YEAR="1993">
<REFERENCE MODIFIED="2012-03-07 15:09:43 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Molina M, Cabello M, Tinahones F, Burgos D, Lillo J, Soriguer F, et al</AU>
<TI>Hyperlipoproteinemia in renal transplant patients: Effect of hypocaloric diet, exercise and HMG-CoA reductase inhibition</TI>
<SO>Nefrologia</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>4</NO>
<PG>359-64</PG>
<IDENTIFIERS MODIFIED="2012-03-07 15:09:43 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="EMBASE" VALUE="1996302763"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:32:45 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Molina M, Cabello M</AU>
<TI>Effect of diet, exercise and HMG-CoA reductase on hypercholesterolaemia in renal transplant patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>9</NO>
<PG>1040</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:32:45 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:32:45 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00260885"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilbrands-1993" MODIFIED="2012-03-07 15:10:13 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Hilbrands 1993" YEAR="1995 Jun">
<REFERENCE MODIFIED="2011-10-23 14:09:32 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA</AU>
<TI>The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>12</NO>
<PG>2073-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7579056"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-07 15:10:13 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilbrands LB, Demacker PN, Hoitsma AJ</AU>
<TI>Cyclosporin and serum lipids in renal transplant recipients</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8847</NO>
<PG>765-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8095674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ichimaru-2001" MODIFIED="2011-10-23 14:10:11 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Ichimaru 2001" YEAR="2001 Oct">
<REFERENCE MODIFIED="2011-10-23 14:10:11 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, et al</AU>
<TI>Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus</TI>
<SO>Atherosclerosis</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>2</NO>
<PG>417-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11583721"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imamura-2005" MODIFIED="2011-10-23 14:10:15 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Imamura 2005" YEAR="2005 Oct">
<REFERENCE MODIFIED="2011-10-23 14:10:15 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imamura R, Ichimaru N, Moriyama T, Shi Y, Namba Y, Nonomura N, et al</AU>
<TI>Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus</TI>
<SO>Clinical Transplantation</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>616-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16146552"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan_x002d_301-2000" MODIFIED="2014-01-15 14:33:31 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Kahan-301 2000" YEAR="2001">
<REFERENCE MODIFIED="2014-01-15 14:33:31 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campistol JM, Legendre C, Castegneto M, Hartmann A, European US Global and Tri-Continental Study Groups</AU>
<TI>The effect of sirolimus on lipids on renal transplant recipients: results from clinical trials [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>880A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:33:31 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:33:31 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550752"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan_x002d_251-2001" MODIFIED="2014-01-15 14:34:21 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Kaplan-251 2001" YEAR="2002">
<REFERENCE MODIFIED="2014-01-15 14:34:21 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kovarik JM, Hartmann S, Berthier S, Hubert M, Rordorf C, Somberg K</AU>
<TI>Statin therapy in renal transplant patients receiving everolimus: screening for clinical and pharmacokinetic drug interactions [abstract no:187]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>Suppl 3</NO>
<PG>185</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:34:21 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:34:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00416055"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasiske-1990" MODIFIED="2011-10-23 14:11:02 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Kasiske 1990" YEAR="1990 Jan">
<REFERENCE MODIFIED="2011-10-23 14:11:02 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV</AU>
<TI>Lovastatin treatment of hypercholesterolemia in renal transplant recipients</TI>
<SO>Transplantation</SO>
<YR>1990</YR>
<VL>49</VL>
<NO>1</NO>
<PG>95-100</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2105548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kliem-1996" MODIFIED="2011-10-23 14:11:12 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Kliem 1996" YEAR="1996 Dec">
<REFERENCE MODIFIED="2011-10-23 14:11:12 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, et al</AU>
<TI>Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine</TI>
<SO>Transplantation Proceedings</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>6</NO>
<PG>3126-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8962211"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lal-1992" MODIFIED="2014-01-15 14:36:33 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lal 1992" YEAR="1995 Apr">
<REFERENCE MODIFIED="2011-10-28 18:49:17 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross G</AU>
<TI>Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>4</NO>
<PG>616-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7702060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:35:08 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal SM, Petroski GF, Hewett JE, Van Stone JC, Ross G</AU>
<TI>Long term lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no:76P]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>Program &amp; Abstracts</NO>
<PG>946</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:35:08 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:35:08 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00484737"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:35:53 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal SM, Petroski GF, Hewett JE, Van Stone JC, Ross G</AU>
<TI>Three year follow up data on the lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no: 372]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>1100</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:35:53 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:35:53 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00484738"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-15 14:36:33 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal SM, Van Stone J, Ross G Jr</AU>
<TI>Lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>866</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:36:33 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:36:33 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00461132"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lal-1996" MODIFIED="2014-01-15 14:38:29 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lal 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-01-15 14:38:29 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal SM, Ross G</AU>
<TI>Lipid lowering effects of gemfibrozil and pravastatin with or without cholestyramine in diabetic renal transplant patients [abstract no: A3342]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1915</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:38:29 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:38:29 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00775367"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lal-1998" MODIFIED="2014-01-15 14:39:13 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lal 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-01-15 14:39:13 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal SM, Habib S</AU>
<TI>Lipid lowering effects of niacin and lovastatin given alone or with cholestyramine in renal transplant patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>683A</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:39:13 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:39:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00446257"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LANDMARK-2-2009" MODIFIED="2014-04-14 08:10:14 +1000" MODIFIED_BY="Gail Y Higgins" NAME="LANDMARK 2 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-01-15 14:39:54 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaisar M, Armstrong K, Prins J, Marwick T, Johnson D, Hawley C, et al</AU>
<TI>The impact of aggressive cardiovascular risk modification on carotid intima media thickness and brachial artery reactivity in renal transplant recipients [abstract no: 132]</TI>
<SO>Nephrology</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>Suppl 3</NO>
<PG>A134</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:39:54 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:39:54 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00766731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:11:30 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaisar MO, Armstrong K, Hawley C, Campbell S, Mudge D, Johnson DW, et al</AU>
<TI>Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study</TI>
<SO>BMC Nephrology</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19821969"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopau-2006" MODIFIED="2011-10-23 14:11:40 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lopau 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-23 14:11:40 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopau K, Spindler K, Wanner C</AU>
<TI>Effects of pravastatin treatment on blood pressure regulation after renal transplantation</TI>
<SO>Kidney &amp; Blood Pressure Research</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>6</NO>
<PG>329-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17124431"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markell-1995" MODIFIED="2014-01-15 14:40:39 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Markell 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-01-15 14:40:39 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markell MS, Sumrani N, Brown CD, Hong JH, Sommer BG, Friedman EA</AU>
<TI>Effect of hypercholesterolemia and lipid-lowering therapy on glomerular filtration rate in renal transplants [abstract no: 1808]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>1103</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:40:39 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:40:39 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00484981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nart-2009" MODIFIED="2011-10-23 14:12:32 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Nart 2009" YEAR="2009 Mar">
<REFERENCE MODIFIED="2011-10-23 14:12:32 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nart A, Uslu A, Bozkaya G, Aykas A, Dogan M, Karaca B</AU>
<TI>A prudent algorithm for hyperlipoproteinemia in renal transplant recipients</TI>
<SO>Transplantation Proceedings</SO>
<YR>2009</YR>
<VL>41</VL>
<NO>2</NO>
<PG>751-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19328972"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicholson-1993" MODIFIED="2014-01-15 14:41:27 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Nicholson 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-01-15 14:41:27 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicholson PG, Raval DD, Behrens MT, Weir MR</AU>
<TI>A prospective cross over trial to compare the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients [abstract no: 76P]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>Program &amp; Abstracts</NO>
<PG>952</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:41:27 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:41:27 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00485241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ok-1996" MODIFIED="2011-10-23 14:13:03 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Ok 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-10-23 14:13:03 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ok E, Kursat S, Alev M, Tobu M, Tokat Y, Akcicek F, et al</AU>
<TI>Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients</TI>
<SO>Nephron</SO>
<YR>1996</YR>
<VL>73</VL>
<NO>3</NO>
<PG>491-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8832618"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olbricht-1997" MODIFIED="2014-01-15 14:42:01 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Olbricht 1997" YEAR="1997 Sep">
<REFERENCE MODIFIED="2014-01-15 14:42:01 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olbricht C, Wanner C, Eisenhauer T, Christians U, Kliem V, O'Grady P, et al</AU>
<TI>Pravastatin and lovastatin pharmacokinetics and pharmacodynamics in renal transplant patients receiving cyclosporine [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>1061</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:42:01 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:42:01 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00485312"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 14:13:07 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, et al</AU>
<TI>Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1997</YR>
<VL>62</VL>
<NO>3</NO>
<PG>311-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9333107"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raiola-1996" MODIFIED="2014-01-15 14:42:42 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Raiola 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-01-15 14:42:42 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raiola P, Manzo M, Saggese A</AU>
<TI>Interaction of cyclosporine and fluvastatin with and without niacin in renal transplant patients with dyslipoproteinemia [abstract no: A3368]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1920</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:42:42 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:42:42 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00775265"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renders-2010" MODIFIED="2013-12-19 11:01:52 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Renders 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-19 11:01:52 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<AU>Renders L</AU>
<TI>Cardiovascular events in renal Transplant recipients with low LDL-cholesterol receiving tacrolimus in combination with the statin fluvastatin [CRANOC]</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00223041</SO>
<YR>(accessed 19 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00223041"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rigatto-1997" MODIFIED="2011-10-23 14:13:28 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Rigatto 1997" YEAR="1997 Sep">
<REFERENCE MODIFIED="2011-10-23 14:13:28 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rigatto O, Rush D, Perry Y, Walker S, Bose R, Bolli P</AU>
<TI>Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>6</NO>
<PG>2591-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9290755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-1997" MODIFIED="2012-03-07 15:11:37 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Rodriguez 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-03-07 15:11:37 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez AP, De Bonis E, Gonzalez PJ, Torres A, Perez L, Dominguez ML, et al</AU>
<TI>Treatment of hyperlipidemia after renal transplantation: Comparative effect of lovastatin and omega-3 fatty acids</TI>
<SO>Nefrologia</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>49-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="1997130521"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz-2006" MODIFIED="2014-10-08 14:10:43 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Ruiz 2006" NOTES="&lt;p&gt;Incorrectly cited - should be 2004&lt;/p&gt;" NOTES_MODIFIED="2014-10-08 14:10:43 +1100" NOTES_MODIFIED_BY="Gail Y Higgins" YEAR="2006 Oct">
<REFERENCE MODIFIED="2011-10-23 14:13:45 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz MC, Moreno JM, Ruiz N, Vargas F, Asensio C, Osuna A</AU>
<TI>Effect of statin treatment on oxidative stress and renal function in renal transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>8</NO>
<PG>2431-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17097958"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turk-2001" MODIFIED="2011-10-23 14:14:54 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Turk 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-10-23 14:14:54 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turk S, Yildiz A, Tukek T, Akkaya V, Aras U, Turkmen A, et al</AU>
<TI>The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>4</NO>
<PG>713-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11989571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasquez-2004" MODIFIED="2014-01-15 14:43:55 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Vasquez 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-01-15 14:43:55 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasquez EM, Sifontis N, Jacobssen V, Testa G, Sankary H, Benedetti E</AU>
<TI>Simvastatin for prevention of bone loss following renal transplantation [abstract no: P284]</TI>
<SO>Transplantation</SO>
<YR>2004</YR>
<VL>78</VL>
<NO>2 Suppl</NO>
<PG>293</PG>
<IDENTIFIERS MODIFIED="2014-01-15 14:43:55 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-01-15 14:43:55 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00509537"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1996" MODIFIED="2012-03-07 15:11:57 +1100" MODIFIED_BY="Suetonia Palmer" NAME="White 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-07 15:11:57 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>White M, Hanes D, Wiland A, Klassen D, Hoen-Saric E, Schweitzer E, et al</AU>
<TI>Long-term treatment of hyperlipidemia in transplant recipients with pravastatin and gemfibrozil [abstract]</TI>
<SO>15th Annual Meeting American Society of Transplant Physicians (ASTP);1996 May 10-14; Chicago (ILL)</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wissing-2006" MODIFIED="2012-03-07 15:12:06 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Wissing 2006" YEAR="2006 Sep 27">
<REFERENCE MODIFIED="2012-03-07 15:12:06 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, Carpentier Y, et al</AU>
<TI>Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation</TI>
<SO>Transplantation</SO>
<YR>2006</YR>
<VL>82</VL>
<NO>6</NO>
<PG>771-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17006324"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-03-06 11:40:41 +1100" MODIFIED_BY="Gail Y Higgins"/>
<ONGOING_STUDIES MODIFIED="2013-12-19 11:02:31 +1100" MODIFIED_BY="Gail Y Higgins">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00565474" MODIFIED="2013-12-19 11:02:31 +1100" MODIFIED_BY="Suetonia Palmer" NAME="NCT00565474" YEAR="">
<REFERENCE MODIFIED="2013-12-19 11:02:31 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00565474</AU>
<TI>Evaluation of the effect of fluvastatin 40 mg (b.i.d.) in the prevention of the development of vasculopathy of the graft in de novo renal transplant patients transplant</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00565474</SO>
<YR>(accessed 19 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00565474"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-19 11:38:26 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-19 11:38:26 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aakhus-1999" MODIFIED="2009-02-02 11:29:35 +1100" MODIFIED_BY="[Empty name]" NAME="Aakhus 1999" TYPE="JOURNAL_ARTICLE">
<AU>Aakhus S, Dahl K, Wideroe TE</AU>
<TI>Cardiovascular morbidity and risk factors in renal transplant patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>3</NO>
<PG>648-54</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:29:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:29:35 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10193814"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aker-1998" MODIFIED="2009-02-02 11:29:41 +1100" MODIFIED_BY="[Empty name]" NAME="Aker 1998" TYPE="JOURNAL_ARTICLE">
<AU>Aker S, Ivens K, Grabensee B, Heering P</AU>
<TI>Cardiovascular risk factors and diseases after renal transplantation</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>6</NO>
<PG>777-88</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:29:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:29:41 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10195874"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ALLHAT-2002" MODIFIED="2009-02-02 11:29:51 +1100" MODIFIED_BY="[Empty name]" NAME="ALLHAT 2002" TYPE="JOURNAL_ARTICLE">
<AU>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial</AU>
<TI>Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>23</NO>
<PG>2998-3007</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:29:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:29:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12479764"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ANZDATA-2010" MODIFIED="2013-12-19 11:11:13 +1100" MODIFIED_BY="Suetonia Palmer" NAME="ANZDATA 2010" TYPE="OTHER">
<AU>Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)</AU>
<TI>The 33rd Annual Report 2010</TI>
<SO>http://www.anzdata.org.au/v1/report_2010.html</SO>
<YR>(accessed 19 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baigent-2005" MODIFIED="2012-03-07 15:12:41 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Baigent 2005" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al</AU>
<TI>Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9493</NO>
<PG>1267-78</PG>
<IDENTIFIERS MODIFIED="2012-03-07 15:12:41 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2012-03-07 15:12:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16214597"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Briel-2006" MODIFIED="2012-03-07 15:12:52 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Briel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al</AU>
<TI>Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>17</NO>
<PG>2046-56</PG>
<IDENTIFIERS MODIFIED="2012-03-07 15:12:52 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2012-03-07 15:12:52 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16670413"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Claesson-1998" MODIFIED="2009-02-02 11:30:12 +1100" MODIFIED_BY="[Empty name]" NAME="Claesson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Claesson K, Mayer AD, Squifflet JP, Grabensee B, Eigler FW, Behrend M, et al</AU>
<TI>Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients</TI>
<SO>Transplantation Proceedings</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>4</NO>
<PG>1292-4</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:12 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:12 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9636524"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Corsini-1993" MODIFIED="2009-02-02 11:30:18 +1100" MODIFIED_BY="[Empty name]" NAME="Corsini 1993" TYPE="JOURNAL_ARTICLE">
<AU>Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, et al</AU>
<TI>Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase</TI>
<SO>Atherosclerosis</SO>
<YR>1993</YR>
<VL>10</VL>
<NO>1</NO>
<PG>117-25</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:18 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8216498"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cosio-2002" MODIFIED="2009-02-02 11:30:23 +1100" MODIFIED_BY="[Empty name]" NAME="Cosio 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S, et al</AU>
<TI>Patient survival after renal transplantation III: the effects of statins</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>3</NO>
<PG>638-43</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:23 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:23 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12200817"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CTT-Collaboration-2010" MODIFIED="2012-03-20 11:15:13 +1100" MODIFIED_BY="Suetonia Palmer" NAME="CTT Collaboration 2010" TYPE="JOURNAL_ARTICLE">
<AU>Cholesterol Treatment Trialists&#8217; (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al</AU>
<TI>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9753</NO>
<PG>1670-1681</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Del-Castillo-2004" MODIFIED="2009-02-02 11:30:27 +1100" MODIFIED_BY="[Empty name]" NAME="Del Castillo 2004" TYPE="JOURNAL_ARTICLE">
<AU>Del Castillo D, Cruzado JM, Manel Diaz J</AU>
<TI>The effects of hyperlipidaemia on graft and patient outcome in renal transplantation</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>Suppl 3</NO>
<PG>iii67-71</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:27 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:27 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15192140"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EBPG-2002" MODIFIED="2009-02-02 11:30:39 +1100" MODIFIED_BY="[Empty name]" NAME="EBPG 2002" TYPE="JOURNAL_ARTICLE">
<AU>EBPG Expert Group on Renal Transplantation</AU>
<TI>European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>26-8</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:39 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:39 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12091631"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fellstrom-2004" MODIFIED="2009-02-02 11:30:47 +1100" MODIFIED_BY="[Empty name]" NAME="Fellstrom 2004" TYPE="JOURNAL_ARTICLE">
<AU>Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, et al</AU>
<TI>Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>4</NO>
<PG>1549-55</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:47 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:47 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15458450"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flechner-2002" MODIFIED="2009-01-19 15:11:34 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Flechner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al</AU>
<TI>Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine</TI>
<SO>Transplantation</SO>
<YR>2002</YR>
<VL>74</VL>
<NO>8</NO>
<PG>1070-6</PG>
<IDENTIFIERS MODIFIED="2009-01-19 15:11:21 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 15:11:21 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="12438948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Groth-1999" MODIFIED="2009-02-02 11:30:52 +1100" MODIFIED_BY="[Empty name]" NAME="Groth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al</AU>
<TI>Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group</TI>
<SO>Transplantation</SO>
<YR>1999</YR>
<VL>67</VL>
<NO>7</NO>
<PG>1036-42</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:30:52 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:30:52 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10221490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2012-03-07 15:16:51 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2012-03-07 15:16:51 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2012-03-07 15:16:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18436948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2012-03-07 15:17:00 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS MODIFIED="2012-03-07 15:17:00 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2012-03-07 15:17:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16345038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hilbrands-1995" MODIFIED="2009-02-02 11:31:29 +1100" MODIFIED_BY="[Empty name]" NAME="Hilbrands 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA</AU>
<TI>The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>12</NO>
<PG>2073-81</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:31:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:31:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7579056"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-HPS-2003" MODIFIED="2009-02-02 11:31:40 +1100" MODIFIED_BY="[Empty name]" NAME="HPS 2003" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9374</NO>
<PG>2005-16</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:31:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:31:40 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12814710"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Isoneimi-1994" MODIFIED="2009-02-02 11:31:46 +1100" MODIFIED_BY="[Empty name]" NAME="Isoneimi 1994" TYPE="JOURNAL_ARTICLE">
<AU>Isoniemi H, Nurminen M, Tikkanen, von Willebrand E, Krogerus L, Ahonen J, et al</AU>
<TI>Risk factors predicting chronic rejection of renal allografts</TI>
<SO>Transplantation</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>1</NO>
<PG>68-72</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:31:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:31:46 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8291116"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jardine-2011" MODIFIED="2012-03-07 15:17:18 +1100" MODIFIED_BY="[Empty name]" NAME="Jardine 2011" TYPE="JOURNAL_ARTICLE">
<AU>Jardine AG, Gaston RS, Fellstrom BC, Holdaas H</AU>
<TI>Prevention of cardiovascular disease in adult recipients of kidney transplants</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>15</VL>
<PG>1419-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-John-1999" MODIFIED="2009-02-02 11:33:14 +1100" MODIFIED_BY="[Empty name]" NAME="John 1999" TYPE="JOURNAL_ARTICLE">
<AU>John GT, Dakshinamurthy DS, Jeyaseelan, Jacob CK</AU>
<TI>The effect of cyclosporine A on plasma lipids during the first year after transplantation</TI>
<SO>National Medical Journal of India</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>1</NO>
<PG>14-7</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:32:15 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:32:15 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10326324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-JUPITER-2008" MODIFIED="2012-03-07 15:17:38 +1100" MODIFIED_BY="Suetonia Palmer" NAME="JUPITER 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al</AU>
<TI>Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>21</NO>
<PG>2195-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kasiske-1996" MODIFIED="2009-02-02 11:33:22 +1100" MODIFIED_BY="[Empty name]" NAME="Kasiske 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske BL, Guijarro C, Massy ZA, Wiederkher MR, Ma JZ</AU>
<TI>Cardiovascular disease after renal transplantation</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>1</NO>
<PG>158-65</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:33:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:33:22 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8808124"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kasiske-2004" MODIFIED="2009-02-02 11:33:29 +1100" MODIFIED_BY="[Empty name]" NAME="Kasiske 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, et al</AU>
<TI>Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>Suppl 7</NO>
<PG>13-53</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:33:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:33:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15027968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDIGO-2009" MODIFIED="2012-03-07 15:18:09 +1100" MODIFIED_BY="[Empty name]" NAME="KDIGO 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group</AU>
<TI>KDIGO clinical practice guideline for the care of kidney transplant recipients</TI>
<SO>Am J Transplant</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>S1-155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurakata-1996" MODIFIED="2009-02-02 11:33:33 +1100" MODIFIED_BY="[Empty name]" NAME="Kurakata 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K</AU>
<TI>Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro</TI>
<SO>Immunopharmacology</SO>
<YR>1996</YR>
<VL>34</VL>
<NO>1</NO>
<PG>51-61</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:33:33 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:33:33 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8880225"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lentine-2004" MODIFIED="2009-01-20 09:51:27 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Lentine 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lentine KL, Brennan DC</AU>
<TI>Statin use after renal transplantation: a systematic quality review of trial-based evidence</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>9</NO>
<PG>2378-86</PG>
<IDENTIFIERS MODIFIED="2009-01-20 09:51:27 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-20 09:51:27 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15252155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lentine-2005" MODIFIED="2012-03-14 12:13:38 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lentine 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lentine KL, Brennan DC, Schnitzler MA</AU>
<TI>Incidence and predictors of myocardial infarction after kidney transplantation</TI>
<SO>Journal of the American Society of Nephrology : JASN</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>2</NO>
<PG>496-506</PG>
<IDENTIFIERS MODIFIED="2012-03-14 12:13:36 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER TYPE="PUBMED" VALUE="15615820"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Massy-1996" MODIFIED="2009-02-02 11:33:45 +1100" MODIFIED_BY="[Empty name]" NAME="Massy 1996" TYPE="JOURNAL_ARTICLE">
<AU>Massy ZA, Keane WF, Kasiske BL</AU>
<TI>Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>8994</NO>
<PG>102-3</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:33:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:33:45 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8538301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Massy-2001" MODIFIED="2009-02-02 11:33:50 +1100" MODIFIED_BY="[Empty name]" NAME="Massy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Massy ZA</AU>
<TI>Hyperlipidemia and cardiovascular disease after organ transplantation</TI>
<SO>Transplantation</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>6 Suppl</NO>
<PG>S13-5</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:33:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:33:50 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11585238"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mathis-2004" MODIFIED="2009-01-20 09:54:13 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Mathis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mathis AS, Dave N, Knipp GT, Friedman GS</AU>
<TI>Drug-related dyslipidemia after renal transplantation</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>6</NO>
<PG>565-85</PG>
<IDENTIFIERS MODIFIED="2009-01-20 09:54:11 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-20 09:54:11 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15061429"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mehra-2004" MODIFIED="2009-01-20 09:55:30 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Mehra 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mehra MR, Raval NY</AU>
<TI>Metaanalysis of statins and survival in de novo cardiac transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1539-41</PG>
<IDENTIFIERS MODIFIED="2009-01-20 09:55:30 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-20 09:55:30 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="15251380"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navaneethan-2009a" MODIFIED="2013-12-18 16:21:05 +1100" MODIFIED_BY="[Empty name]" NAME="Navaneethan 2009a" TYPE="COCHRANE_REVIEW">
<AU>Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al</AU>
<TI>HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-12-18 16:00:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 16:00:03 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007784"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NKF-2002" MODIFIED="2009-02-02 11:33:57 +1100" MODIFIED_BY="[Empty name]" NAME="NKF 2002" TYPE="JOURNAL_ARTICLE">
<AU>National Kidney Foundation</AU>
<TI>K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>2</NO>
<PG>S1-S266</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:33:57 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:33:57 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11904577"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2013" MODIFIED="2013-12-18 15:57:49 +1100" MODIFIED_BY="[Empty name]" NAME="Palmer 2013" TYPE="COCHRANE_REVIEW">
<AU>Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, et al</AU>
<TI>HMG CoA reductase inhibitors (statins) for dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2013-12-18 15:57:31 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:57:31 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004289.pub5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Raine-1988" MODIFIED="2009-01-20 09:58:50 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Raine 1988" TYPE="JOURNAL_ARTICLE">
<AU>Raine AE, Carter R, Mann JI, Morris PJ</AU>
<TI>Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>4</NO>
<PG>458-63</PG>
<IDENTIFIERS MODIFIED="2009-01-20 09:58:47 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-20 09:58:47 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="3140134"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Satterthwaite-1998" MODIFIED="2009-01-19 15:22:51 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Satterthwaite 1998" TYPE="JOURNAL_ARTICLE">
<AU>Satterthwaite R, Aswad S, Sunga V, Shidban H, Bogaard T, Asai P, et al</AU>
<TI>Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine</TI>
<SO>Transplantation</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>3</NO>
<PG>446-9</PG>
<IDENTIFIERS MODIFIED="2009-01-19 15:22:38 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-01-19 15:22:38 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9484771"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sever-2003" MODIFIED="2009-02-02 11:34:27 +1100" MODIFIED_BY="[Empty name]" NAME="Sever 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al</AU>
<TI>Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9364</NO>
<PG>1149-58</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:34:27 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:34:27 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12686036"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SHARP-2011" MODIFIED="2013-12-19 11:38:26 +1100" MODIFIED_BY="[Empty name]" NAME="SHARP 2011" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al</AU>
<TI>The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>377</VL>
<PG>2181-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shepherd-1995" MODIFIED="2009-02-02 11:34:39 +1100" MODIFIED_BY="[Empty name]" NAME="Shepherd 1995" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al</AU>
<TI>Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>20</NO>
<PG>1301-7</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:34:39 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:34:39 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7566020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-USRDS-2011" MODIFIED="2011-12-07 10:46:04 +1100" MODIFIED_BY="[Empty name]" NAME="USRDS 2011" TYPE="OTHER">
<AU>USRDS</AU>
<TI>USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD</TI>
<SO>http://www.usrds.org/2011/pdf/v2_ch04_11.pdf</SO>
<YR>2011</YR>
<IDENTIFIERS MODIFIED="2009-02-02 11:34:55 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:34:55 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14655174"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vathsala-1989" MODIFIED="2009-02-02 11:35:00 +1100" MODIFIED_BY="[Empty name]" NAME="Vathsala 1989" TYPE="JOURNAL_ARTICLE">
<AU>Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, Van Buren CT, et al</AU>
<TI>Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients</TI>
<SO>Transplantation</SO>
<YR>1989</YR>
<VL>48</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS MODIFIED="2009-02-02 11:35:00 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-02 11:35:00 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2665233"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-12-18 16:20:58 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Navaneethan-2009b" MODIFIED="2013-12-18 16:20:58 +1100" MODIFIED_BY="[Empty name]" NAME="Navaneethan 2009b" TYPE="COCHRANE_PROTOCOL">
<AU>Navaneethan SD, Perkovic V, Nigwekar SU, Johnson DW, Craig JC, Strippoli GF</AU>
<TI>HMG CoA reductase inhibitors (statins) for kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-11-27 14:21:39 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-27 14:21:39 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005019.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navaneethan-2009c" MODIFIED="2013-12-18 16:20:48 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Navaneethan 2009c" TYPE="COCHRANE_REVIEW">
<AU>Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF</AU>
<TI>HMG CoA reductase inhibitors (statins) for kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005019.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perkovic-2004" MODIFIED="2012-03-07 12:13:50 +1100" MODIFIED_BY="Narelle S Willis" NAME="Perkovic 2004" TYPE="COCHRANE_PROTOCOL">
<AU>Perkovic V, Craig JC, Masterson R, Webster A</AU>
<TI>HMG CoA reductase inhibitors (statins) for kidney transplant patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-03-07 12:13:45 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2012-03-07 12:13:45 +1100" MODIFIED_BY="Suetonia Palmer" TYPE="DOI" VALUE="10.1002/14651858.CD005019"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-12-19 14:20:11 +1100" MODIFIED_BY="Gail Y Higgins"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-01-15 14:50:22 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-12-18 11:34:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ALERT-2001">
<CHAR_METHODS MODIFIED="2013-11-27 16:03:19 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration/enrolment period: June 1996 to October 1997</LI>
<LI>Follow-up: 5 to 6 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-18 11:34:41 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: nephrology and transplant units</LI>
<LI>Country: multiple European countries + Canada</LI>
<LI>KTR or combined kidney and pancreas transplant recipients</LI>
<LI>Number: treatment group (1050); control group (1052)</LI>
<LI>Mean age SD (years): treatment group (49.5 ± 10.9); control group (50.0 ± 11.0)</LI>
<LI>Sex (males): treatment group (66.6%); control group (65.2%)</LI>
<LI>Exclusion criteria: patients on statins; familial hypercholesterolaemia; acute rejection within previous 3 months; predicted life expectancy &lt; 1 year</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 15:38:37 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin 40 mg</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 11:56:56 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Clinical outcomes</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-27 15:51:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Publication type: journal publication</LI>
<LI>Withdrawals: fluvastatin (5), placebo (3); reasons unclear</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-05 18:06:47 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnadottir-1994">
<CHAR_METHODS MODIFIED="2013-12-05 17:21:38 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Study follow-up:</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:06:47 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: Sweden</LI>
<LI>Cyclosporin treated KTR with serum TC &gt; 6.5 mmol/L despite dietary treatment</LI>
<LI>Number: treatment group (20); control group (20)</LI>
<LI>Mean age SD (years): treatment group (55 ± 9); control group (48 ± 12)</LI>
<LI>Sex (males): treatment group (70%); control group (60%)</LI>
<LI>Exclusion criteria: patients on statins; hepatitis, myopathy; TG &gt; 4.5 mmol/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-27 15:48:11 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin 20 to 40 mg</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 12:06:35 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-27 15:48:03 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Publication type: journal publication</LI>
<LI>Withdrawals: simvastatin (1); placebo (2)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bill-1995">
<CHAR_METHODS MODIFIED="2013-12-05 16:48:39 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: 32 weeks</LI>
<LI>Study follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:07:10 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Poland</LI>
<LI>Good and stable graft function (SCr &lt; 2 mg/dL)</LI>
<LI>Number (analysed/randomised): treatment group (15/21); control group (18/21)</LI>
<LI>Mean age; range (years): treatment group (35; 20-57); control group (39.3; 25-53)</LI>
<LI>Sex (M/F): treatment group (11/4); control group (12/6)</LI>
<LI>Exclusion criteria: impaired liver function; diabetes; active peptic ulcer disease; history of gastrointestinal bleeding; polyneuropathy; cataract; obesity &gt; 30% adequate body mass; gastrointestinal disorders; pregnancy; women who plan to conceive; ovariohysterectomy; alcohol abusers; heavy smokers (&gt; 10 cigarettes/d)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:52:19 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Lovastatin 10 mg/d to 20 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-19 11:41:03 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Kidney outcomes (SCr, proteinuria)</LI>
<LI>Cardiovascular outcomes (BP)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-27 15:56:54 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Publication type: journal publication</LI>
<LI>Withdrawals: lovastatin (6 due to non-compliance); placebo (3, reason not stated)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-18 09:52:28 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castelao-1993">
<CHAR_METHODS MODIFIED="2013-12-05 17:21:06 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:07:27 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: Spain</LI>
<LI>KTR</LI>
<LI>Number: treatment group 1 (25); treatment group 2 (26)</LI>
<LI>Mean age ± SD (years): treatment group 1 (44 ± 10); treatment group 2 (43 ± 11)</LI>
<LI>Sex (males): treatment group 1 (64%); treatment group 2 (73.1%)</LI>
<LI>Exclusion criteria: patients on statins; hepatitis; myopathy; serum TG &gt; 4.5 mmol/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:52:28 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Lovastatin 20 mg/d</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Simvastatin 10 mg/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 13:21:00 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-05 17:06:21 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-05 18:07:43 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Celik-2000a">
<CHAR_METHODS MODIFIED="2013-12-05 17:15:08 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: randomised cross-over study</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:07:43 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: teaching hospital, single centre</LI>
<LI>Country: Turkey</LI>
<LI>Transplanted 6 months ago, stable kidney allograft function with creatinine &lt; 2.5 mg/dL and TC &gt; 240 mg/dL after six month lipid lowering diet</LI>
<LI>Number: 20</LI>
<LI>Mean age ± SD (years): 35 ± 11</LI>
<LI>Sex (M/F): 12/8</LI>
<LI>Exclusion criteria: proteinuria &gt; 1 g; presence of abnormal liver tests</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-05 17:10:20 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Simvastatin 20 mg/d</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Simvastatin 10 mg/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-05 17:10:26 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Apolipoprotein</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:08:03 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cofan-2002">
<CHAR_METHODS MODIFIED="2013-12-05 17:18:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:08:14 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: Spain</LI>
<LI>Cyclosporin-treated KTR with moderate hypercholesterolaemia despite dietary treatment</LI>
<LI>Number: treatment group (30); control group (17)</LI>
<LI>Mean age ± SD: 55 ± 7 years</LI>
<LI>Sex: 63.8% males</LI>
<LI>Exclusion criteria: patients on statins; hepatic disease; diabetes mellitus; previous clinical cardiovascular disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-19 11:16:41 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Pravastatin 20 mg/d</LI>
<LI>Hypolipidaemic diet</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Hypolipidaemic diet</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 13:25:12 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-05 17:16:36 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-05 18:08:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hausberg-2001">
<CHAR_METHODS MODIFIED="2013-12-05 17:30:08 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:08:32 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Germany</LI>
<LI>SCr &lt; 2.5 mg/dL, TC 200 to 350 mg/dL</LI>
<LI>Number: treatment group (18); control group (18)</LI>
<LI>Mean age ± SEM (years): treatment group (50 ± 2); control group (47 ± 3)</LI>
<LI>Sex (M/F): treatment group (13/5); control group (13/5)</LI>
<LI>Exclusion criteria: prior use of statins; previous history of cardiovascular disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-05 17:26:38 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin 40 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-05 17:26:50 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Flow mediated vasodilation</LI>
<LI>CK levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:09:14 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasiske-2001">
<CHAR_METHODS MODIFIED="2013-12-19 11:17:01 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 26 February 1996 to 16 March 1999</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 13:27:52 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: USA</LI>
<LI>Cyclosporin treated adult cadaveric and living-related donor KTR</LI>
<LI>Number: treatment group (53); control group (52)</LI>
<LI>Mean age; 95% CI (years): treatment group (46; 43 to 50); control group (47; 43 to 51)</LI>
<LI>Sex (males): treatment group (66%); control group (51.9%)</LI>
<LI>Exclusion criteria: six-antigen-matched cadaveric or two-haplotype-matched living-related donor transplants; hepatic disease; TC &gt; 350 mg/dL</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:52:52 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin 10 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 13:34:22 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
<LI>Clinical outcomes</LI>
<LI>Acute allograft rejection</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-05 17:39:36 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-18 09:52:56 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katznelson-1996">
<CHAR_METHODS MODIFIED="2013-12-05 17:48:50 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:09:04 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: USA</LI>
<LI>Cadaveric KTR</LI>
<LI>Number: treatment group (24); control group (24)</LI>
<LI>Mean age ± SD (years): treatment group (46.5 ± 2.6); control group (48.0 ± 2.5)</LI>
<LI>Sex (males): treatment group (71%); control group (72%)</LI>
<LI>Exclusion criteria: patients on statins; antilymphocyte preparations</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:52:56 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Pravastatin 20 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 13:37:26 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Acute allograft rejection</LI>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
<LI>Clinical outcomes</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-05 17:40:51 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-19 11:17:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lepre-1999">
<CHAR_METHODS MODIFIED="2013-12-12 13:07:18 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT (2:1)</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-19 11:17:41 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: Australia</LI>
<LI>KTR with TC &gt; 6 mmol/L while on a low-saturated fat diet</LI>
<LI>Number: treatment group (32); control group (17)</LI>
<LI>Mean age ± SD (years): treatment group (52 ± 13.2); control group (50.2 ± 11.9)</LI>
<LI>Sex (M/F): treatment group (10/22); control group (7/10)</LI>
<LI>Exclusion criteria: patients on statins; hepatic disease; myocardial infarction within previous 3 months; known alcohol/drug abuse</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 13:08:14 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin 5 mg for 6 weeks then 10 mg for 6 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 13:47:45 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-05 17:52:38 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-12 13:23:05 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez-Hernandez-1993">
<CHAR_METHODS MODIFIED="2013-12-05 18:00:04 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 13:23:05 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: NS</LI>
<LI>Country: UK</LI>
<LI>KTR with TC &gt; 7.0 mmol/L on 3 occasions over 3 months</LI>
<LI>Number: 23</LI>
<LI>Mean age ± SD: 47.5 ± 9.7 years</LI>
<LI>Sex (M/F): 13/10</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 13:15:27 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin 5 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-02 15:48:01 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-05 17:59:32 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Publication type: Journal publication</LI>
<LI>Simvastatin (side effects (1), non-compliance (1)); placebo (side effects (1))</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-12 13:17:29 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Melchor-1998">
<CHAR_METHODS MODIFIED="2013-12-12 13:17:29 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-05 18:18:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: teaching hospital, single-centre</LI>
<LI>Country: Mexico</LI>
<LI>KTR, TC &gt; 220 mg/dL with failure to reduce lipid levels with diet for 4 weeks; all patients treated with fluvastatin for 16 weeks</LI>
<LI>Number: treatment group (22); control group (20)</LI>
<LI>Mean age ± SD (years): treatment group (38.8 ± 9.4); control group (38.8 ± 9.4)</LI>
<LI>Sex (M/F): treatment group (19/23); control group (19/23)</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-05 18:16:23 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin 20 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-05 18:01:54 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>ALT, AST</LI>
<LI>SCr</LI>
<LI>CPK</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:12:21 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-18 09:54:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raiola-1998">
<CHAR_METHODS MODIFIED="2013-12-12 13:18:46 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 13:31:08 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: teaching hospital, single centre</LI>
<LI>Country: Italy</LI>
<LI>KTR with hypercholesterolaemia (LDL &gt; 160 mg/dL) and hypertriglyceridaemia (&gt; 180 mg/dL)</LI>
<LI>Number: treatment group (15); control group (15)</LI>
<LI>Age range: 19 to 60 years</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:54:09 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Atorvastatin 10 mg/d for 8 weeks</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Fluvastatin 20 mg/d for 8 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-12 13:16:44 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Liver enzyme levels, CPK levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-09 05:46:59 +1100" MODIFIED_BY="[Empty name]">
<P>Abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-12 13:38:02 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Renders-2001">
<CHAR_METHODS MODIFIED="2013-12-12 13:33:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: </LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 13:37:27 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Germany</LI>
<LI>KTR, stable cyclosporin dosage, LDL &#8805; 130 mg/dL</LI>
<LI>Number: treatment group (10); control group (10)</LI>
<LI>Mean age ± SD (years): treatment group (52 ± 14); control group (49 ± 14)</LI>
<LI>Sex (M/F): treatment group (8/2); control group (2/8)</LI>
<LI>Exclusion criteria: MI within previous 6 months; known coronary heart disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 13:38:02 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin 10 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-03 14:06:35 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-12 13:31:53 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-12 13:44:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sahu-2001">
<CHAR_METHODS MODIFIED="2013-12-12 13:41:26 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: transplanted between December 1997 to June 1999</LI>
<LI>Follow-up: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 13:44:13 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: India</LI>
<LI>One-haplotype-matched, living-related first KTR; first 3 months post-transplant</LI>
<LI>Number: treatment group (33); control group (32)</LI>
<LI>Mean age ± SD (years): treatment group (38.7 ± 8.6); control group (37.4 ± 9.2)</LI>
<LI>Sex (M/F): treatment group (26/7); control group (27/5)</LI>
<LI>Exclusion criteria: spousal transplants, second transplants, hepatitis, anti-lymphocyte induction protocol</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 13:44:41 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Lovastatin 20 mg/d for 3 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-03 14:10:52 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Acute rejection episodes</LI>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-12 13:38:51 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-19 11:18:08 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santos-2001">
<CHAR_METHODS MODIFIED="2013-12-12 13:52:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: 180 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-19 11:18:08 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: outpatient clinic; single centre</LI>
<LI>Country: Brazil</LI>
<LI>Adult KTR; TC &gt; 200 mg/dL, LDL &gt; 130 mg/dL, TG &lt; 400 mg/dL after 8 weeks of supervised diet</LI>
<LI>Number: treatment group (34); control group (32)</LI>
<LI>Mean age ± SD (years): treatment group (44.3 ± 11.2); control group (42.2 ± 10.7)</LI>
<LI>Sex (M/F): treatment group (15/19); control group (15/18)</LI>
<LI>Exclusion criteria: MI within previous 6 months; heart failure; nephrotic syndrome; abnormal baseline LFT</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 13:50:56 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin 10 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-03 14:22:40 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-12 13:45:15 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-12 14:09:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seron-2008">
<CHAR_METHODS MODIFIED="2013-12-12 14:09:38 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 13:58:00 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: multicentre</LI>
<LI>Country: Spain</LI>
<LI>Adult KTR of a first or second kidney transplant obtained from a deceased donor, aged between 18 and 70 years</LI>
<LI>Number: treatment group (45); control group (44)</LI>
<LI>Mean age ± SD (years): treatment (41 ± 16); control group (43 ± 15)</LI>
<LI>Sex (M/F): treatment group (27/18); control group (25/19)</LI>
<LI>Exclusion criteria: patients with TC &gt; 6.2 mmol/L (240 mg/dL), diabetes mellitus, or at least one major adverse cardiovascular event before transplantation</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 13:53:37 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin 80 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-12 13:59:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Progression of mean intimal arterial volume fraction (Vvintima/artery) evaluated in the donor and 6-month protocol biopsy</LI>
<LI>Incidence of IF/TA with transplant vasculopathy, (chronic allograft nephropathy type b), the prevalence of subclinical rejection and biopsy-proven acute rejection, serum creatinine, and proteinuria at 6 months, patient and graft survival</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:14:18 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharif-2009">
<CHAR_METHODS MODIFIED="2013-12-12 14:15:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over RCT; 4 week wash-out period</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-12 14:18:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre, University Hospital of Wales, Cardiff</LI>
<LI>Country: UK</LI>
<LI>Caucasian, nondiabetic (based upon oral glucose tolerance test), stable graft function aged over 6 months, tacrolimus-based immunosuppression and either current statin use or desired (defined as fasting TC &gt; 4.5 mmol/L or fasting LDL &gt;2.5 mmol/L)</LI>
<LI>Number: 20</LI>
<LI>Mean age (range): 56 (32 to 72) years</LI>
<LI>Sex (M/F):16/4</LI>
<LI>Exclusion criteria: diabetes; history of cardiovascular disease; fasting TC &gt; 8.0 mmol/L; pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 14:18:37 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Rosuvastatin 10 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-12 14:19:33 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters</LI>
<LI>eGFR</LI>
<LI>Changes in insulin sensitivity and insulin secretion</LI>
<LI>HbA1C</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:14:27 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SOLAR-Study-2001">
<CHAR_METHODS MODIFIED="2013-12-12 14:35:35 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: January 1998 to June 1999</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-19 11:21:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: international, multicentre (11) study</LI>
<LI>Country: Norway, Sweden, Finland, UK, Ireland</LI>
<LI>18 years or older, receiving cadaveric or living-related kidney allografts</LI>
<LI>Number: treatment group (182); control group (182)</LI>
<LI>Mean age ± SD (years): treatment group (49.1 ± 13.5); control group (47.7 ± 14.8)</LI>
<LI>Sex (M/F): treatment group (130/52); control group (130/52)</LI>
<LI>Exclusion criteria: patients with malignant disease; serological evidence of HIV or HBsAg; able randomisation number starting from the beginning; systemic infection; pregnancy; those using inadequate patients with a living donor graft were assigned the next contraceptive measures</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-12 14:23:44 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin 40 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-12 14:19:29 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Acute allograft rejection</LI>
<LI>Lipid parameters</LI>
<LI>Adverse events</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:04:58 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuncer-2000">
<CHAR_METHODS MODIFIED="2013-12-12 15:03:34 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: January 1994 to April 1998</LI>
<LI>Follow-up:</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-15 13:18:46 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Turkey</LI>
<LI>First-graft deceased or living-donor KTR</LI>
<LI>Number: treatment group 1 (16); treatment group 2 (16); control group (25)</LI>
<LI>Mean ± age SD (years): treatment group 1 (42.8 ± 4.5); treatment group 2 (40.7 ± 2.6); control group (41.4 ± 3.9)</LI>
<LI>Sex (M/F): treatment group 1 (10/6); treatment group 2 (9/7); control group (16/9</LI>
<LI>Exclusion criteria: statins within 1 month of transplantation</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-15 13:18:58 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Simvastatin 10 mg/d</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Pravastatin 20 mg/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-18 09:20:28 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Acute allograft rejection</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-12 14:59:20 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<CHAR_METHODS MODIFIED="2013-12-18 09:29:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 1999 to March 2001</LI>
<LI>Follow-up: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-19 11:39:39 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre</LI>
<LI>Country: UK</LI>
<LI>Adult patients with functional kidney transplant (subset of study)</LI>
<LI>Number: treatment group (65); control group (68)</LI>
<LI>Age: Unclear</LI>
<LI>Sex (M/F): Unclear</LI>
<LI>Exclusion criteria: patients on statins; recent history of acute uraemia; chronic liver disease; inflammatory muscle disease or CK level greater than 3 times the upper limit of normal; previous adverse reaction to a statin or history of aspirin hypersensitivity; concurrent treatment with a contraindicated drug; high immediate risk for bleeding; child-bearing potential in the absence of a reliable method of contraception; a life-threatening condition other than CKD or vascular disease; frequent nonattendance at clinics; known noncompliance with drug treatments; alcohol or substance abuse</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:45:59 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin 20 mg/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-03 14:41:14 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-15 13:18:15 +1100" MODIFIED_BY="[Empty name]">
<P>Publication type: Journal publication</P>
<P>This was 4-arm study with aspirin used alone and in combination with simvastatin. Simvastatin-aspirin/simvastatin alone and double placebo/aspirin placebo groups were combined for this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-19 11:22:11 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vergoulas-1999">
<CHAR_METHODS MODIFIED="2013-12-18 09:43:24 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-19 11:22:11 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: single centre</LI>
<LI>Country: Greece</LI>
<LI>Hypercholesterolaemic KTR</LI>
<LI>Number: treatment group (22); control group (28)</LI>
<LI>Mean age (years): treatment group (40); control group (41)</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 09:54:55 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Lovastatin 20 mg/d</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Fluvastatin 40 mg/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-18 09:32:18 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters</LI>
<LI>CPK</LI>
<LI>SGOT, SGPT levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-23 14:15:00 +1100" MODIFIED_BY="Suetonia Palmer"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALT - alanine aminotransferase; AST - aspartate aminotransferase; BP - blood pressure; CABG - coronary artery bypass graft; CAD - coronary artery disease; CK - creatine kinase; CKD - chronic kidney disease; CRP - C-reactive protein; CV - cardiovascular; DM - diabetes mellitus; HDL - high-density lipoprotein; HRT - hormone replacement therapy; KTR - kidney transplant recipients; LDL - low-density lipoprotein; LFT - liver function tests; MI - myocardial infarction; NS - not stated; SCr - serum creatinine; TC - total cholesterol; TG - triglycerides</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-12-18 11:09:26 +1100" MODIFIED_BY="Suetonia Palmer" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:18:48 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Bagdade-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:18:48 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:54 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Blechman_x002d_Krom-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:54 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:19:04 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Blum-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:19:04 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:19:14 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Capone-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:19:14 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:55 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Castro-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:55 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:55 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Cheng-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:55 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:20:02 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Curtis-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:20:02 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:09:26 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Garcia_x002d_de_x002d_la_x002d_Puente-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:09:26 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Paediatric population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:56 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Gonzalez_x002d_Molina-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:56 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:20:31 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Hilbrands-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:20:31 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:20:43 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ichimaru-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:20:43 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:20:45 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Imamura-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:20:45 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:25:22 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kahan_x002d_301-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:25:22 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:25:39 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kaplan_x002d_251-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:25:39 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:21:16 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kasiske-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:21:16 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:21:27 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kliem-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:21:27 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:56 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lal-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:56 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:57 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lal-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:57 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:57 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lal-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:57 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:21:56 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-LANDMARK-2-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:21:56 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:22:06 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lopau-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:22:06 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:22:18 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Markell-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:22:18 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:22:28 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Nart-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:22:28 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:22:41 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Nicholson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:22:41 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:22:53 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ok-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:22:53 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:23:15 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Olbricht-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:23:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:23:26 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Raiola-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:23:26 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:58 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Renders-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:58 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Terminated (unclear)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:23:38 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Rigatto-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:23:38 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:59 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Rodriguez-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:59 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:24:13 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ruiz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:24:13 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:24:22 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Turk-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:24:22 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-18 11:08:59 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Vasquez-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-18 11:08:59 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-06 11:41:04 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-White-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-06 11:41:04 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Active (non-statin) intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 14:24:44 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Wissing-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 14:24:44 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-03-06 11:40:41 +1100" MODIFIED_BY="Gail Y Higgins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-01-15 14:50:22 +1100" MODIFIED_BY="Gail Y Higgins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-01-15 14:50:22 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-NCT00565474">
<CHAR_STUDY_NAME MODIFIED="2013-12-18 11:16:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Evaluation of the effect of fluvastatin 40 mg (b.i.d.) in the prevention of the development of vasculopathy of the graft in de novo renal transplant patients transplant</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-10-23 14:28:27 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Randomised, parallel-group, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-15 14:50:22 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Inclusion criteria</P>
<UL>
<LI>Patients where the investigator expects to prescribe cyclosporine, mycophenolate mofetil and corticosteroids as base immunosuppressive therapy, regardless of their participation in the study</LI>
<LI>Man or woman aged from 17 to 70 years.</LI>
<LI>Patients that receive a first or second renal transplant from a non-living donor</LI>
<LI>Patients where allograft biopsies may be performed.</LI>
<LI>Patients receiving an identical or compatible ABO graft.</LI>
<LI>Patients willing to give their written informed consent to all study issues.</LI>
<LI>Women with child-bearing potential should use a medically proven contraceptive method during the study.</LI>
<LI>Patients able to meet all study requirements.</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients with pre-transplant cholesterol levels above 240 mg/dL (6.2 mmol/L)</LI>
<LI>Positive cross-match of T cells or ABO incompatibility with the donor</LI>
<LI>Recipients of multiorgan transplant</LI>
<LI>Patients with diabetes mellitus</LI>
<LI>HIV seropositive or with surface antigen of Hepatitis B</LI>
<LI>Kidney from a donor aged over 65 years</LI>
<LI>Last panel of reactive antibody (PRA) above 50%</LI>
<LI>Women who plan to get pregnant within 12 months, or who are pregnant and/or nursing</LI>
<LI>Patients with a history of cancer in the previous 5 years, except for patients successfully treated with localized carcinoma of squamous or basal cells of the skin, or cervix cancer in situ treated adequately</LI>
<LI>Patients receiving an investigational drug in the 30 days prior to the transplant and/or who will receive an investigational/non-registered drug during the study, except for the use of erythropoietin-stimulating products</LI>
<LI>Patients with myocardial infarction within the 6 months prior to the transplant, uncontrollable cardiac arrhythmia or another severe or unstable medical condition probably affecting the safety of the patient or the study objectives</LI>
<LI>Patients with alcohol dependence or drug abuse not solved, or signs of organic lesion caused by alcohol, mental dysfunction or other factors limiting their ability to fully cooperate with the study.</LI>
<LI>Patients where it is planned to perform an induction treatment with preparations containing antilymphocyte antibodies (ALG, ATG or OKT-3)</LI>
<LI>Patients scheduled to receive cyclosporine IV for over 48 hours.</LI>
<LI>Patients with liver dysfunction (ALT or AST values or total bilirubin 2 times above the upper limit of the normal ranges of the laboratory values)</LI>
<LI>Other protocol-defined inclusion/exclusion criteria may apply</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-18 11:14:01 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Fluvastatin 40 mg twice daily versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-18 11:16:35 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Primary outcome measures: to determine if treatment with fluvastatin can prevent the progression of vascular graft disease. The difference between the vascular intimal thickness measured on the baseline biopsy and the biopsy at the end of the study between the two treatment group</P>
<P>Secondary outcome measures: 24-hour creatinine and proteinuria values at 6 months post-transplant, graft survival and patient survival at 6 months, differences in lipid profile between the treatment groups, incidence of rejection episodes treated and documented by biopsy at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-23 14:29:17 +1100" MODIFIED_BY="Suetonia Palmer">
<P>September 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-10-23 14:29:38 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Novartis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-10-23 14:12:36 +1100" MODIFIED_BY="Suetonia Palmer"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-01-15 13:09:10 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-01-15 13:05:41 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:40:41 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-ALERT-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:45:28 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Arnadottir-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-15 13:05:41 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bill-1995">
<DESCRIPTION>
<P>"Every other patient was given Lovastatin 20 mg/night"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:48:58 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Castelao-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:49:48 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2000a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:50:15 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Cofan-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:50:53 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Hausberg-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:52:04 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Kasiske-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:54:55 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Katznelson-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:57:19 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Lepre-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:59:45 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-Hernandez-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:03:53 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Melchor-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:16:24 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Raiola-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:08:39 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Renders-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:28:06 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SOLAR-Study-2001">
<DESCRIPTION>
<P>Centralized randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:08:59 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sahu-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:11:57 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 13:28:31 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seron-2008">
<DESCRIPTION>
<P>Randomisation schedule was generated by the data operating department of Clinical Data Care. Patients were randomised by means of a computer-generated scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:24:09 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sharif-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:30:37 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-18 09:02:58 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<DESCRIPTION>
<P>Minimized randomisation was used to balance the treatment groups; 2 X 2 factorial design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:08:14 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vergoulas-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-01-15 13:05:57 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:40:46 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ALERT-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:46:20 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arnadottir-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:07:04 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bill-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:49:03 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castelao-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:49:52 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2000a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:50:19 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cofan-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:50:56 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Hausberg-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-15 13:05:57 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kasiske-2001">
<DESCRIPTION>
<P>"Investigators in each center were blinded to simvastatin and to the randomization sequence."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:54:56 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katznelson-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:57:20 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lepre-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:59:46 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-Hernandez-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:03:55 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Melchor-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:16:31 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Raiola-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:08:40 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Renders-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:28:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SOLAR-Study-2001">
<DESCRIPTION>
<P>Each medication pack was labelled with a study identification code and randomisation number. Randomization was stratified by centre and blocked pseudo-randomisation was performed by the producer centrally. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:09:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sahu-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:11:59 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:22:06 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Seron-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:24:16 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sharif-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:30:44 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:04:58 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<DESCRIPTION>
<P>Randomisation was by telephone to the Clinical Trial Service Unit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:08:22 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vergoulas-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-05 01:30:27 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-12-05 16:52:42 +1100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-12-05 16:52:42 +1100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-01-15 13:06:08 +1100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:43:22 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ALERT-2001">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:47:08 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arnadottir-1994">
<DESCRIPTION>
<P>Double blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 20:07:17 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bill-1995">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:49:19 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Castelao-1993">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:49:55 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2000a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:50:30 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cofan-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:51:50 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hausberg-2001">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-15 13:06:08 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kasiske-2001">
<DESCRIPTION>
<P>"Patients in all three groups were blinded to simvastatin. Investigators in each center were blinded to simvastatin and to the randomization sequence."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:57:01 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katznelson-1996">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 19:57:46 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lepre-1999">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 20:00:43 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-Hernandez-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 20:04:02 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Melchor-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:16:33 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raiola-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:17:08 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Renders-2001">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:28:40 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SOLAR-Study-2001">
<DESCRIPTION>
<P>All study personnel directly involved in the conduct of the study were blinded to treatment until all patients had completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-02 20:09:38 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sahu-2001">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:19:32 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santos-2001">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:23:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seron-2008">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:25:00 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharif-2009">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 09:30:50 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 16:06:23 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<DESCRIPTION>
<P>Matching placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 16:08:32 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vergoulas-1999">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-12-19 11:16:04 +1100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-19 11:16:04 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ALERT-2001">
<DESCRIPTION>
<P>An independent critical events committee of two nephrologists and two cardiologists who were unaware of treatment assignment reviewed all primary and secondary endpoints for adjudication. All analyses were based in the committee's classification of endpoints which were agreed by consensus or majority vote</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:47:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arnadottir-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-05 17:00:35 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bill-1995">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:49:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Castelao-1993">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:49:56 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2000a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:50:37 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cofan-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:51:53 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Hausberg-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:54:39 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Kasiske-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:57:03 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Katznelson-1996">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 19:59:00 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Lepre-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 20:01:04 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-Hernandez-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 20:04:03 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Melchor-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 09:16:34 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raiola-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 09:17:18 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Renders-2001">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 09:28:41 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SOLAR-Study-2001">
<DESCRIPTION>
<P>All study personnel directly involved in the conduct of the study were blinded to treatment until all patients had completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-02 20:09:37 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sahu-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 09:19:35 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 12:00:18 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seron-2008">
<DESCRIPTION>
<P>Biopsies were blindly evaluated by the same observer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 09:25:03 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sharif-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 09:31:35 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tuncer-2000">
<DESCRIPTION>
<P>Core biopsies were examined by a pathologist who was blinded to patient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 16:07:49 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<DESCRIPTION>
<P>All events were coded centrally according to a standard protocol. Otherwise unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 16:08:36 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vergoulas-1999">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-01-15 13:09:10 +1100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 15:53:57 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ALERT-2001">
<DESCRIPTION>
<P>All randomised participants included in intention-to-treat analysis. 7 participants (&lt; 1%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 17:01:20 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-1994">
<DESCRIPTION>
<P>3/20 patients did not complete the study (15%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 17:00:45 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Bill-1995">
<DESCRIPTION>
<P>9/42 (21%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 16:53:24 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Castelao-1993">
<DESCRIPTION>
<P>Not clearly described; no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-02 19:49:53 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2000a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-15 13:08:21 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Cofan-2002">
<DESCRIPTION>
<P>Pravastatin (3); placebo (1); all due to loss of follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 17:33:30 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hausberg-2001">
<DESCRIPTION>
<P>4/40 patients (10%) dropped out during follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-18 16:01:53 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kasiske-2001">
<DESCRIPTION>
<P>26/140 patients incomplete cholesterol data, 57/140 patients incomplete LDL data; no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 17:40:38 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katznelson-1996">
<DESCRIPTION>
<P>2/24 patients lost to follow-up in control group; no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 17:53:05 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lepre-1999">
<DESCRIPTION>
<P>3/52 patients did not complete study (6%) (musculoskeletal pain (2); abdominal pain (1))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 17:59:18 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinez-Hernandez-1993">
<DESCRIPTION>
<P>4/26 (15%) did not finish study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-05 18:17:07 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Melchor-1998">
<DESCRIPTION>
<P>Not described; 2 patients refused to continue fluvastatin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 09:16:32 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Raiola-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-02 20:08:43 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Renders-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-15 13:09:10 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SOLAR-Study-2001">
<DESCRIPTION>
<P>83% of the patients who commenced the study completed the protocol with no difference between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 15:54:26 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sahu-2001">
<DESCRIPTION>
<P>All participants included in follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 09:19:24 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santos-2001">
<DESCRIPTION>
<P>6 of 67 (9%) patients not included in end of treatment assessments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-12 13:28:43 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seron-2008">
<DESCRIPTION>
<P>89 patients were included, 74 completed the 6 month study, and 57 had paired biopsies with sufficient tissue for histological evaluation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 15:54:27 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharif-2009">
<DESCRIPTION>
<P>No patient lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 09:30:49 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-27 15:54:27 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<DESCRIPTION>
<P>442 of 448 patients completed follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 16:08:27 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vergoulas-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2013-12-05 16:52:05 +1100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Intention to treat analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 13:21:30 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ALERT-2001">
<DESCRIPTION>
<P>Intention-to-treat analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:47:35 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-1994">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:07:27 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bill-1995">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:49:36 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Castelao-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:49:57 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Celik-2000a">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:50:41 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Cofan-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:51:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hausberg-2001">
<DESCRIPTION>
<P>Not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-24 11:16:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kasiske-2001">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:57:08 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katznelson-1996">
<DESCRIPTION>
<P>Not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 19:59:04 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lepre-1999">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:01:15 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinez-Hernandez-1993">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:04:04 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Melchor-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:16:35 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Raiola-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:08:45 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Renders-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:29:19 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SOLAR-Study-2001">
<DESCRIPTION>
<P>Intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 20:11:49 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sahu-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:19:54 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santos-2001">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:23:47 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seron-2008">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:25:14 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sharif-2009">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 09:31:40 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:07:43 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:08:55 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vergoulas-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-18 11:12:15 +1100" MODIFIED_BY="Suetonia Palmer">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-12-18 11:12:15 +1100" MODIFIED_BY="Suetonia Palmer" NO="1">
<TITLE MODIFIED="2012-03-05 12:01:50 +1100" MODIFIED_BY="Suetonia Palmer">Summary of findings</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD COLSPAN="6">
<P>
<B>Statin versus placebo or no treatment for adults kidney transplant recipients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: adults with chronic kidney disease</B>
</P>
<P>
<B>Settings: kidney transplant recipients</B>
</P>
<P>
<B>Intervention: statin</B>
</P>
<P>
<B>Comparison: placebo or no treatment</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo or no treatment</P>
</TH>
<TH VALIGN="TOP">
<P>Statin</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Major cardiovascular events</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 per 1000 </B>(13 to 21)</P>
<P>
<B>3 fewer</B> (7 fewer to 1 more)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.84</B>
</P>
<P>(0.66 to 1.06)</P>
</TD>
<TD VALIGN="TOP">
<P>2102 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>22 per 1000 </B>(12 to 37)</P>
<P>
<B>2 more </B>(8 fewer to 17 more)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.08</B>
</P>
<P>(0.63 to 1.83)</P>
</TD>
<TD VALIGN="TOP">
<P>2760 (6)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cardiovascular mortality</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3 per 1000 </B>(2 to 5)</P>
<P>
<B>2 fewer </B>(3 fewer to 0 more)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.68</B>
</P>
<P>(0.45 to 1.01)</P>
</TD>
<TD VALIGN="TOP">
<P>2322 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Absolute approximate event rates of outcomes/year were derived from previously published observational cohort studies. Absolute numbers of people with a functioning kidney transplant with cardiovascular or mortality events avoided or incurred per 1000 treated were estimated using these assumed risks together with the estimated relative risks (and 95% confidence intervals) (<LINK REF="REF-ANZDATA-2010" TYPE="REFERENCE">ANZDATA 2010</LINK>; <LINK REF="REF-Lentine-2005" TYPE="REFERENCE">Lentine 2005</LINK>).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-12-19 11:41:29 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-12-19 11:41:29 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-02-03 15:56:55 +1100" MODIFIED_BY="[Empty name]">Published guidelines on hyperlipidaemia management with statins in kidney transplant patients</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>
<B>Guidelines</B>
</P>
</TH>
<TH>
<P>
<B>Country</B>
</P>
</TH>
<TH>
<P>
<B>Year</B>
</P>
</TH>
<TH>
<P>
<B>Lipid parameters</B>
</P>
</TH>
<TH>
<P>
<B>Treatment</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Kidney Disease Improving Global Outcomes (<LINK REF="REF-KDIGO-2009" TYPE="REFERENCE">KDIGO 2009</LINK>)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>2009</P>
</TD>
<TD>
<P>LDL &#8805;100 mg/dL</P>
</TD>
<TD>
<P>TLC + statin</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>National Kidney Foundation Disease Outcomes Quality initiative (NKF-DOQI) (<LINK REF="REF-NKF-2002" TYPE="REFERENCE">NKF 2002</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2004</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>LDL 100-129 mg/dL</LI>
<LI>LDL &gt; 130 mg/dL</LI>
<LI>TG &gt; 200 mg/dL and non-HDL &gt; 130 mg/dL</LI>
</OL>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>TLC + low dose statin</LI>
<LI>TLC + maximum dose statin</LI>
<LI>TLC + maximum dose statin</LI>
</OL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>European Best Practice Guidelines (<LINK REF="REF-EBPG-2002" TYPE="REFERENCE">EBPG 2002</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>Europe</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>LDL &gt; 130 mg/dL</P>
</TD>
<TD VALIGN="TOP">
<P>TLC + low dose statin</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Canadian Society of Nephrology (CSN)</P>
</TD>
<TD VALIGN="TOP">
<P>Canada</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline available</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline available</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>British Renal Association (BRA)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>UK</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline available</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Caring for Australians with Renal Impairment (CARI)</P>
</TD>
<TD VALIGN="TOP">
<P>Australia</P>
</TD>
<TD VALIGN="TOP">
<P>2004</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline available</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline available</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>LDL- low-density lipoprotein cholesterol; Non-HDL - Non high-density lipoprotein cholesterol; TC - total cholesterol; TG - triglycerides; TLC - therapeutic lifestyle changes</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Statins versus placebo</NAME>
<DICH_OUTCOME CHI2="2.067396131804515" CI_END="1.011499215180455" CI_START="0.45228510040240216" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6763771315581589" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.004965550139023255" LOG_CI_START="-0.3445877189522948" LOG_EFFECT_SIZE="-0.16981108440663578" METHOD="IV" MODIFIED="2013-12-18 14:50:42 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5585369023191095" P_Q="1.0" P_Z="0.056873757347255104" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1161" TOTAL_2="1161" WEIGHT="100.0" Z="1.9042797710225376">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.675398384618285" CI_START="0.013660868459919703" EFFECT_SIZE="0.3238095238095238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8851009263969365" LOG_CI_START="-1.8645216904523023" LOG_EFFECT_SIZE="-0.4897103820276829" MODIFIED="2011-11-05 06:33:35 +1100" MODIFIED_BY="[Empty name]" ORDER="1050" O_E="0.0" SE="1.6151419359887094" STUDY_ID="STD-Santos-2001" TOTAL_1="34" TOTAL_2="33" VAR="2.608683473389356" WEIGHT="1.616145857489091"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1045" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="1.6299019287442504"/>
<DICH_DATA CI_END="99.81977876234554" CI_START="0.24126127868519828" EFFECT_SIZE="4.907407407407407" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992166029735117" LOG_CI_START="-0.6175123747458332" LOG_EFFECT_SIZE="0.6908521141138394" ORDER="1044" O_E="0.0" SE="1.5370795545296865" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" VAR="2.362613556953179" WEIGHT="1.7844699894363685"/>
<DICH_DATA CI_END="1.0094412178196632" CI_START="0.44196647685741663" EFFECT_SIZE="0.6679365079365079" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="54" LOG_CI_END="0.0040810340078988195" LOG_CI_START="-0.354610670623697" LOG_EFFECT_SIZE="-0.17526481830789906" ORDER="1043" O_E="0.0" SE="0.21069728285317307" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.044393345001710015" WEIGHT="94.96948222433029"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.4934740422319175" CI_END="1.8346346687439208" CI_START="0.632998161528523" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0776457545925713" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="144" I2="8.982913879964858" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2635495960297047" LOG_CI_START="-0.1985975513399547" LOG_EFFECT_SIZE="0.032476022344874955" METHOD="IV" MODIFIED="2013-12-18 14:51:04 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.358662100205824" P_Q="1.0" P_Z="0.7829618307693702" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08137541664436046" TOTALS="YES" TOTAL_1="1382" TOTAL_2="1378" WEIGHT="100.00000000000003" Z="0.2754613309607192">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.13351438889974" CI_START="0.0126165022026235" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8533035415877801" LOG_CI_START="-1.8990610321484551" LOG_EFFECT_SIZE="-0.5228787452803376" MODIFIED="2011-11-05 06:31:54 +1100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.6167525750370366" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" VAR="2.613888888888889" WEIGHT="2.734225929751391"/>
<DICH_DATA CI_END="7.675398384618285" CI_START="0.013660868459919703" EFFECT_SIZE="0.3238095238095238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8851009263969365" LOG_CI_START="-1.8645216904523023" LOG_EFFECT_SIZE="-0.4897103820276829" MODIFIED="2011-11-05 06:30:45 +1100" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="0.0" SE="1.6151419359887094" STUDY_ID="STD-Santos-2001" TOTAL_1="34" TOTAL_2="33" VAR="2.608683473389356" WEIGHT="2.739516810960975"/>
<DICH_DATA CI_END="3.958599447956658" CI_START="0.010104583837257678" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5975415597610922" LOG_CI_START="-1.9954815684331297" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1032" O_E="0.0" SE="1.5231546211727816" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" VAR="2.32" WEIGHT="3.0688502516696623"/>
<DICH_DATA CI_END="160.06699556269538" CI_START="0.48746949677840207" EFFECT_SIZE="8.833333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2043017933644258" LOG_CI_START="-0.3120525549301348" LOG_EFFECT_SIZE="0.9461246192171454" ORDER="1031" O_E="0.0" SE="1.4781190003431393" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" VAR="2.1848357791754016" WEIGHT="3.2518864814171096"/>
<DICH_DATA CI_END="12.720207601133398" CI_START="0.4913441821062034" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1044941993069655" LOG_CI_START="-0.3086141819628902" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-11-05 06:31:32 +1100" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.8300668581572144" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="182" VAR="0.689010989010989" WEIGHT="9.565928860664876"/>
<DICH_DATA CI_END="1.2907018024922468" CI_START="0.8351045829908458" EFFECT_SIZE="1.0382056590752242" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="138" LOG_CI_END="0.11082591655677759" LOG_CI_START="-0.07825913293356268" LOG_EFFECT_SIZE="0.016283391811607453" ORDER="1030" O_E="0.0" SE="0.11106949405671622" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.01233643251001492" WEIGHT="78.639591665536"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="112" EVENTS_2="134" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-12-18 14:51:04 +1100" MODIFIED_BY="Suetonia Palmer" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="0.0" Z="0.0">
<NAME>Major cardiovascular events</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0602214013838431" CI_START="0.6614282859519829" EFFECT_SIZE="0.8374129353233831" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="134" LOG_CI_END="0.025396566546792537" LOG_CI_START="-0.17951723644048018" LOG_EFFECT_SIZE="-0.0770603349468438" MODIFIED="2012-03-05 10:40:19 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="86" O_E="0.0" SE="0.12036738221440779" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.014488306701149332" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-03-07 12:17:38 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="0.0" Z="0.0">
<NAME>Fatal and non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0075290265675396" CI_START="0.4839751988155553" EFFECT_SIZE="0.6982972582972583" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="66" LOG_CI_END="0.003257566869247208" LOG_CI_START="-0.31517689309427205" LOG_EFFECT_SIZE="-0.15595966311251241" ORDER="1053" O_E="0.0" SE="0.1870499780585699" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.03498769429171148" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="74" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2012-03-07 12:17:50 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="0.0" Z="0.0">
<NAME>Fatal and non-fatal stroke</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6286631320954559" CI_START="0.8503622192090443" EFFECT_SIZE="1.176840513983371" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="63" LOG_CI_END="0.21183126540049899" LOG_CI_START="-0.07039604335014575" LOG_EFFECT_SIZE="0.07071761102517665" MODIFIED="2012-01-03 18:15:19 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="242" O_E="0.0" SE="0.16578171820783832" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.02748357809194311" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45180034520984447" CI_END="1.888081192730888" CI_START="0.390398520718886" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8585476717336601" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.2760206662315481" LOG_CI_START="-0.40849183661201116" LOG_EFFECT_SIZE="-0.06623558519023152" METHOD="MH" MODIFIED="2013-12-18 15:30:38 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5014812645512159" P_Q="1.0" P_Z="0.7044617046533036" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1117" TOTAL_2="1116" WEIGHT="100.00000000000001" Z="0.37930457348405144">
<NAME>Elevated creatine kinase</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-03 18:44:00 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="260" O_E="0.0" SE="0.0" STUDY_ID="STD-Sahu-2001" TOTAL_1="33" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.13351438889974" CI_START="0.0126165022026235" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8533035415877801" LOG_CI_START="-1.8990610321484551" LOG_EFFECT_SIZE="-0.5228787452803376" MODIFIED="2012-01-03 18:42:24 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="258" O_E="0.0" SE="1.6167525750370366" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" VAR="2.613888888888889" WEIGHT="6.185158759753077"/>
<DICH_DATA CI_END="2.076008828358691" CI_START="0.40786090416853904" EFFECT_SIZE="0.9201754385964912" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3172291960450673" LOG_CI_START="-0.38948792233089674" LOG_EFFECT_SIZE="-0.03612936314291475" MODIFIED="2012-01-03 19:18:44 +1100" MODIFIED_BY="[Empty name]" ORDER="1073" O_E="0.0" SE="0.41512913364019716" STUDY_ID="STD-ALERT-2001" TOTAL_1="1045" TOTAL_2="1049" VAR="0.1723321975968607" WEIGHT="93.81484124024693"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1809387023393152" CI_END="1.1938432680602211" CI_START="0.3263464055995139" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6241846356492845" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.07694731482979959" LOG_CI_START="-0.48632116628926536" LOG_EFFECT_SIZE="-0.2046869257297329" METHOD="MH" MODIFIED="2013-12-18 15:30:39 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5540673888335566" P_Q="1.0" P_Z="0.15431100174252677" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="307" TOTAL_2="301" WEIGHT="100.0" Z="1.4244681390283556">
<NAME>Elevated liver enzymes</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-03 19:19:26 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="261" O_E="0.0" SE="0.0" STUDY_ID="STD-Sahu-2001" TOTAL_1="33" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.66939680154748" CI_START="0.12268044555079471" EFFECT_SIZE="2.9444444444444446" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8492313844111223" LOG_CI_START="-0.9112246554161565" LOG_EFFECT_SIZE="0.469003364497483" MODIFIED="2012-01-03 19:19:21 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="263" O_E="0.0" SE="1.6215055422723186" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" VAR="2.629280223619846" WEIGHT="4.1636021994567605"/>
<DICH_DATA CI_END="6.036853464551696" CI_START="0.13341241339313906" EFFECT_SIZE="0.8974358974358975" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7808106341425284" LOG_CI_START="-0.8748037594949756" LOG_EFFECT_SIZE="-0.046996562676223555" MODIFIED="2012-01-03 19:19:34 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="262" O_E="0.0" SE="0.9725160902460924" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" VAR="0.9457875457875458" WEIGHT="11.57477381766123"/>
<DICH_DATA CI_END="1.114739571000119" CI_START="0.27136383050312274" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" LOG_CI_END="0.047173417977655716" LOG_CI_START="-0.566448038989168" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="1063" O_E="0.0" SE="0.36044428129751194" STUDY_ID="STD-ALERT-2001" TOTAL_1="182" TOTAL_2="182" VAR="0.12992007992007992" WEIGHT="84.26162398288201"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.602634196825289" CI_END="1.0597246842691026" CI_START="0.7445295017369211" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8882546319368061" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="222" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.02519305051644977" LOG_CI_START="-0.12811808879467454" LOG_EFFECT_SIZE="-0.05146251913911243" METHOD="MH" MODIFIED="2013-12-18 15:30:39 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8910799573967243" P_Q="1.0" P_Z="0.1882355492086151" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1422" TOTAL_2="1388" WEIGHT="100.00000000000001" Z="1.3158167699957175">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="50.68318377815582" CI_START="0.13090194014078466" EFFECT_SIZE="2.5757575757575757" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7048638882527445" LOG_CI_START="-0.8830539165799342" LOG_EFFECT_SIZE="0.4109049858364052" MODIFIED="2012-01-03 19:22:05 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1086" O_E="0.0" SE="1.5201557289584529" STUDY_ID="STD-Lepre-1999" TOTAL_1="32" TOTAL_2="16" VAR="2.310873440285205" WEIGHT="0.35095098449127005"/>
<DICH_DATA CI_END="2.6246806717009323" CI_START="0.007775484265703283" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4190764730927677" LOG_CI_START="-2.1092725531212815" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2012-01-03 19:21:52 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="265" O_E="0.0" SE="1.48516473352766" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" VAR="2.2057142857142855" WEIGHT="0.36768284730050177"/>
<DICH_DATA CI_END="14.052704911192018" CI_START="0.07116067734430034" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1477599267279106" LOG_CI_START="-1.1477599267279106" LOG_EFFECT_SIZE="0.0" ORDER="1083" O_E="0.0" SE="1.3483997249264843" STUDY_ID="STD-Martinez-Hernandez-1993" TOTAL_1="11" TOTAL_2="11" VAR="1.8181818181818183" WEIGHT="0.44605181989655146"/>
<DICH_DATA CI_END="5.099739904623853" CI_START="0.046180861186529115" EFFECT_SIZE="0.4852941176470588" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707548026908308" LOG_CI_START="-1.3355379725650056" LOG_EFFECT_SIZE="-0.3139949728283488" ORDER="1087" O_E="0.0" SE="1.2001188295294294" STUDY_ID="STD-Santos-2001" TOTAL_1="34" TOTAL_2="33" VAR="1.4402852049910875" WEIGHT="0.5630852181862407"/>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1081" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Arnadottir-1994" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="0.5792880777877293"/>
<DICH_DATA CI_END="15.092333255049837" CI_START="0.19148795293352114" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1787563863269497" LOG_CI_START="-0.717858543570402" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2012-01-03 19:21:34 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="264" O_E="0.0" SE="1.1140809982170214" STUDY_ID="STD-Cofan-2002" TOTAL_1="30" TOTAL_2="17" VAR="1.241176470588235" WEIGHT="0.653414988215543"/>
<DICH_DATA CI_END="1.5114131860047464" CI_START="0.23683241837338181" EFFECT_SIZE="0.5982905982905983" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.17938320680865844" LOG_CI_START="-0.625558850272468" LOG_EFFECT_SIZE="-0.22308782173190483" MODIFIED="2012-01-03 19:22:53 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="266" O_E="0.0" SE="0.4728269488568979" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" VAR="0.22356532356532355" WEIGHT="3.627589896184655"/>
<DICH_DATA CI_END="1.4592076353317047" CI_START="0.5891524575287809" EFFECT_SIZE="0.9271978021978022" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.16411709344442277" LOG_CI_START="-0.2297723064084472" LOG_EFFECT_SIZE="-0.032827606482012245" MODIFIED="2012-01-03 19:23:26 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="267" O_E="0.0" SE="0.2313725832575508" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="180" VAR="0.053533272283272273" WEIGHT="15.149518688328678"/>
<DICH_DATA CI_END="1.102248195482091" CI_START="0.7395711945022156" EFFECT_SIZE="0.9028792912513842" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="172" LOG_CI_END="0.04227939650465474" LOG_CI_START="-0.13102001248360534" LOG_EFFECT_SIZE="-0.04437030798947527" ORDER="1085" O_E="0.0" SE="0.10179693068561362" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.010362615097011623" WEIGHT="78.26241747960884"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="296" EVENTS_2="316" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-12-18 15:30:40 +1100" MODIFIED_BY="Suetonia Palmer" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1045" TOTAL_2="1049" WEIGHT="0.0" Z="0.0">
<NAME>Cancer</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0744841457619185" CI_START="0.8228632006025215" EFFECT_SIZE="0.9402943492217309" ESTIMABLE="YES" EVENTS_1="296" EVENTS_2="316" LOG_CI_END="0.031200011768912905" LOG_CI_START="-0.08467235939487329" LOG_EFFECT_SIZE="-0.026736173812980196" MODIFIED="2012-03-05 10:47:25 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="89" O_E="0.0" SE="0.06806400439909582" STUDY_ID="STD-ALERT-2001" TOTAL_1="1045" TOTAL_2="1049" VAR="0.004632708694840136" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="86.00682299265937" CI_END="-33.64942389579912" CI_START="-51.21804528726156" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-42.43373459153034" ESTIMABLE="YES" I2="87.21031702224504" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2013-12-19 14:02:19 +1100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0014211682118912E-13" P_Q="1.0" P_Z="2.856453988506318E-21" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="159.07844176495425" TOTALS="YES" TOTAL_1="1543" TOTAL_2="1527" UNITS="mg/dL" WEIGHT="100.00000000000001" Z="9.467856319033334">
<NAME>Total cholesterol</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.924419725554724" CI_START="-48.92441972555473" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="247.0" MEAN_2="264.0" MODIFIED="2013-12-19 14:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="243" SD_1="40.0" SD_2="43.0" SE="16.288268548488887" STUDY_ID="STD-Hausberg-2001" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.733234358339425"/>
<CONT_DATA CI_END="-17.28757983738525" CI_START="-78.71242016261475" EFFECT_SIZE="-48.0" ESTIMABLE="YES" MEAN_1="224.0" MEAN_2="272.0" MODIFIED="2013-12-19 13:31:03 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1088" SD_1="26.0" SD_2="45.0" SE="15.669890061690113" STUDY_ID="STD-Martinez-Hernandez-1993" TOTAL_1="11" TOTAL_2="11" WEIGHT="4.964410281528443"/>
<CONT_DATA CI_END="-27.243382951518228" CI_START="-86.75661704848177" EFFECT_SIZE="-57.0" ESTIMABLE="YES" MEAN_1="192.0" MEAN_2="249.0" MODIFIED="2013-12-19 14:02:13 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1095" SD_1="28.0" SD_2="39.0" SE="15.182226450688976" STUDY_ID="STD-Renders-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.156134979890442"/>
<CONT_DATA CI_END="-40.995910642993735" CI_START="-91.00408935700627" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="212.0" MEAN_2="278.0" MODIFIED="2013-12-19 13:31:07 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1094" SD_1="35.0" SD_2="46.0" SE="12.757422868091114" STUDY_ID="STD-Lepre-1999" TOTAL_1="32" TOTAL_2="17" WEIGHT="6.241547659822259"/>
<CONT_DATA CI_END="-41.10390801015118" CI_START="-84.89609198984883" EFFECT_SIZE="-63.0" ESTIMABLE="YES" MEAN_1="209.0" MEAN_2="272.0" MODIFIED="2013-12-19 13:31:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1096" SD_1="37.0" SD_2="50.0" SE="11.171680787280991" STUDY_ID="STD-Santos-2001" TOTAL_1="31" TOTAL_2="31" WEIGHT="7.075822200661591"/>
<CONT_DATA CI_END="-10.643964718514415" CI_START="-51.35603528148559" EFFECT_SIZE="-31.0" ESTIMABLE="YES" MEAN_1="201.0" MEAN_2="232.0" MODIFIED="2013-12-19 14:02:19 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="244" SD_1="43.0" SD_2="46.0" SE="10.385923130246981" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" WEIGHT="7.524818604505016"/>
<CONT_DATA CI_END="-14.980605364995704" CI_START="-53.019394635004296" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="203.0" MEAN_2="237.0" MODIFIED="2013-12-19 14:02:15 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1092" SD_1="46.0" SD_2="12.0" SE="9.703951085339758" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.931916408714641"/>
<CONT_DATA CI_END="-23.368206634662453" CI_START="-50.63179336533754" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="166.0" MEAN_2="203.0" MODIFIED="2013-12-19 13:31:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="247" SD_1="42.0" SD_2="38.0" SE="6.955124417011431" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005" TOTAL_1="65" TOTAL_2="68" WEIGHT="9.682804308495337"/>
<CONT_DATA CI_END="-12.288777004567855" CI_START="-35.711222995432145" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="211.0" MEAN_2="235.0" MODIFIED="2013-12-19 14:02:16 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="246" SD_1="57.0" SD_2="57.0" SE="5.9752235693149345" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="182" WEIGHT="10.312666098947"/>
<CONT_DATA CI_END="-57.53479596228662" CI_START="-70.46520403771338" EFFECT_SIZE="-64.0" ESTIMABLE="YES" MEAN_1="209.0" MEAN_2="273.0" MODIFIED="2013-12-19 13:31:06 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1091" SD_1="13.0" SD_2="20.0" SE="3.2986341018049745" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" WEIGHT="11.818814915594112"/>
<CONT_DATA CI_END="-35.10566128543314" CI_START="-44.89433871456686" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="182.0" MEAN_2="222.0" MODIFIED="2013-12-19 14:02:18 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1097" SD_1="9.0" SD_2="11.0" SE="2.497157474919324" STUDY_ID="STD-Sahu-2001" TOTAL_1="33" TOTAL_2="32" WEIGHT="12.150913707017082"/>
<CONT_DATA CI_END="-30.70590626773449" CI_START="-37.29409373226551" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="163.0" MEAN_2="197.0" MODIFIED="2013-12-19 14:02:17 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1090" SD_1="37.0" SD_2="40.0" SE="1.6806909505730199" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="12.406916476484673"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="63.76863861460415" CI_END="-33.7825520400974" CI_START="-52.59329466444157" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-43.187923352269486" ESTIMABLE="YES" I2="84.3183103524656" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2013-12-18 15:30:42 +1100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="6.967331156459977E-10" P_Q="1.0" P_Z="2.2606057776015203E-19" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="160.80943129288573" TOTALS="YES" TOTAL_1="1510" TOTAL_2="1494" UNITS="mg/dL" WEIGHT="99.99999999999996" Z="8.999833342887571">
<NAME>LDL cholesterol</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-26.639355411960786" CI_START="-105.36064458803921" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="172.0" ORDER="1106" SD_1="28.0" SD_2="57.0" SE="20.082330542046158" STUDY_ID="STD-Renders-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.082181859874145"/>
<CONT_DATA CI_END="17.62840085423076" CI_START="-51.62840085423076" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="148.0" MEAN_2="165.0" MODIFIED="2012-01-03 18:27:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="248" SD_1="43.0" SD_2="47.0" SE="17.667876107609715" STUDY_ID="STD-Hausberg-2001" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.868871215201468"/>
<CONT_DATA CI_END="-7.546060887336054" CI_START="-72.45393911266395" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="145.0" MEAN_2="185.0" MODIFIED="2012-01-03 18:30:02 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1098" SD_1="30.0" SD_2="46.0" SE="16.558436465494506" STUDY_ID="STD-Martinez-Hernandez-1993" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.293893360357478"/>
<CONT_DATA CI_END="-17.57242125217576" CI_START="-66.42757874782424" EFFECT_SIZE="-42.0" ESTIMABLE="YES" MEAN_1="108.0" MEAN_2="150.0" MODIFIED="2012-01-03 18:29:37 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1102" SD_1="32.0" SD_2="52.0" SE="12.463279397226612" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.284042353872542"/>
<CONT_DATA CI_END="-45.90933199318527" CI_START="-92.09066800681472" EFFECT_SIZE="-69.0" ESTIMABLE="YES" MEAN_1="120.0" MEAN_2="189.0" MODIFIED="2012-01-03 18:29:49 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1104" SD_1="31.0" SD_2="43.0" SE="11.781169546456452" STUDY_ID="STD-Lepre-1999" TOTAL_1="32" TOTAL_2="17" WEIGHT="7.68610107154327"/>
<CONT_DATA CI_END="-43.526498845389185" CI_START="-80.47350115461082" EFFECT_SIZE="-62.0" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="179.0" MODIFIED="2012-01-03 18:30:55 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1107" SD_1="27.0" SD_2="45.0" SE="9.42542888559557" STUDY_ID="STD-Santos-2001" TOTAL_1="31" TOTAL_2="31" WEIGHT="9.224171581881114"/>
<CONT_DATA CI_END="-10.041225536667458" CI_START="-43.958774463332546" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="120.0" MEAN_2="147.0" MODIFIED="2012-01-03 18:31:21 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="249" SD_1="35.0" SD_2="39.0" SE="8.652594944142438" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" WEIGHT="9.770995655080714"/>
<CONT_DATA CI_END="-19.945269765182882" CI_START="-42.054730234817114" EFFECT_SIZE="-31.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="119.0" MODIFIED="2012-01-03 18:32:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="251" SD_1="33.0" SD_2="32.0" SE="5.640272128475533" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005" TOTAL_1="65" TOTAL_2="68" WEIGHT="11.955000364641132"/>
<CONT_DATA CI_END="-19.80129408942905" CI_START="-40.19870591057095" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="144.0" MODIFIED="2012-01-03 18:31:56 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="250" SD_1="47.0" SD_2="52.0" SE="5.203516998790304" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="181" WEIGHT="12.256352451861302"/>
<CONT_DATA CI_END="-53.79923919736359" CI_START="-66.20076080263641" EFFECT_SIZE="-60.0" ESTIMABLE="YES" MEAN_1="109.0" MEAN_2="169.0" MODIFIED="2012-01-03 18:27:41 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1101" SD_1="9.0" SD_2="21.0" SE="3.1637116046760148" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" WEIGHT="13.480959351080793"/>
<CONT_DATA CI_END="-34.87676787704363" CI_START="-41.12323212295637" EFFECT_SIZE="-38.0" ESTIMABLE="YES" MEAN_1="104.0" MEAN_2="142.0" MODIFIED="2012-01-03 18:26:04 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1100" SD_1="35.0" SD_2="38.0" SE="1.5935150582316921" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="14.097430734606018"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="87.36301131813308" CI_END="-1.032444903732328" CI_START="-10.346233619756253" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.689339261744291" ESTIMABLE="YES" I2="88.55350811616952" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2013-12-18 15:30:43 +1100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.8207657603852567E-14" P_Q="1.0" P_Z="0.01664336983945738" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="41.634270068362575" TOTALS="YES" TOTAL_1="1510" TOTAL_2="1495" UNITS="mg/dL" WEIGHT="99.99999999999999" Z="2.3944928082089567">
<NAME>HDL cholesterol</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.550360472475717" CI_START="-13.550360472475717" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="43.0" MODIFIED="2012-01-03 18:34:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1109" SD_1="21.0" SD_2="21.0" SE="8.954430086935638" STUDY_ID="STD-Martinez-Hernandez-1993" TOTAL_1="11" TOTAL_2="11" WEIGHT="4.63438319516909"/>
<CONT_DATA CI_END="15.136331921042247" CI_START="-15.136331921042247" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="66.0" MODIFIED="2012-01-03 18:35:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="253" SD_1="31.0" SD_2="35.0" SE="7.722760234593952" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" WEIGHT="5.574335066943079"/>
<CONT_DATA CI_END="15.837700219689113" CI_START="-11.837700219689113" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="65.0" MODIFIED="2012-01-03 18:33:37 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="252" SD_1="18.0" SD_2="18.0" SE="7.060180864974625" STUDY_ID="STD-Hausberg-2001" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.171182949648413"/>
<CONT_DATA CI_END="12.044858821417092" CI_START="-12.044858821417092" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="58.0" MEAN_2="58.0" MODIFIED="2012-01-03 18:34:37 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1115" SD_1="23.0" SD_2="19.0" SE="6.145449057444627" STUDY_ID="STD-Lepre-1999" TOTAL_1="32" TOTAL_2="17" WEIGHT="7.110033292169247"/>
<CONT_DATA CI_END="1.1653943492946688" CI_START="-19.16539434929467" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="51.0" MEAN_2="60.0" ORDER="1116" SD_1="13.0" SD_2="10.0" SE="5.186520991955976" STUDY_ID="STD-Renders-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.237374261442408"/>
<CONT_DATA CI_END="-1.3648946641232111" CI_START="-20.635105335876787" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="67.0" MODIFIED="2012-01-03 18:34:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1113" SD_1="16.0" SD_2="18.0" SE="4.915960401250875" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="8.579550083932736"/>
<CONT_DATA CI_END="11.325060099633571" CI_START="-3.3250600996335704" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="52.0" MODIFIED="2012-01-03 18:35:12 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1117" SD_1="17.0" SD_2="12.0" SE="3.7373442356148936" STUDY_ID="STD-Santos-2001" TOTAL_1="31" TOTAL_2="31" WEIGHT="10.153273450766829"/>
<CONT_DATA CI_END="-16.339201094911683" CI_START="-29.660798905088317" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="70.0" MODIFIED="2012-01-03 18:36:15 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1108" SD_1="21.0" SD_2="18.0" SE="3.3984292352450605" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005" TOTAL_1="65" TOTAL_2="68" WEIGHT="10.614973869070704"/>
<CONT_DATA CI_END="-8.164439953766507" CI_START="-15.835560046233493" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="51.0" MODIFIED="2012-01-03 18:36:03 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="254" SD_1="21.0" SD_2="16.0" SE="1.9569543504308753" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="182" WEIGHT="12.417366980190279"/>
<CONT_DATA CI_END="-3.704621104236277" CI_START="-8.295378895763722" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="60.0" ORDER="1112" SD_1="6.0" SD_2="6.0" SE="1.171133201359504" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" WEIGHT="13.127116105053037"/>
<CONT_DATA CI_END="1.4633485508890587" CI_START="-1.4633485508890587" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="50.0" MODIFIED="2012-01-03 18:33:18 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1111" SD_1="15.0" SD_2="19.0" SE="0.7466201228347894" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="13.380410745614167"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.69886500613679" CI_END="-20.27497241940405" CI_START="-34.29328155978712" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-27.284126989595585" ESTIMABLE="YES" I2="14.52162244154137" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2013-12-18 15:30:44 +1100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.30571584454269074" P_Q="1.0" P_Z="2.3578032741041006E-14" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="19.107877271705807" TOTALS="YES" TOTAL_1="1515" TOTAL_2="1497" UNITS="mg/dL" WEIGHT="100.0" Z="7.6294374326750365">
<NAME>Triglycerides</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-18.085517136173657" CI_START="-37.91448286382634" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="182.0" MEAN_2="210.0" ORDER="1121" SD_1="100.0" SD_2="130.0" SE="5.058502575573081" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" WEIGHT="28.612991834835622"/>
<CONT_DATA CI_END="50.043013968516206" CI_START="-62.043013968516206" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="163.0" MEAN_2="169.0" MODIFIED="2012-01-03 18:37:29 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="255" SD_1="106.0" SD_2="59.0" SE="28.59389989335332" STUDY_ID="STD-Hausberg-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="1.5284648927410454"/>
<CONT_DATA CI_END="-6.151252675730682" CI_START="-47.84874732426932" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="225.0" MEAN_2="252.0" ORDER="1122" SD_1="55.0" SD_2="54.0" SE="10.637311444864077" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" WEIGHT="9.669537035134509"/>
<CONT_DATA CI_END="-29.791127352288697" CI_START="-46.2088726477113" EFFECT_SIZE="-38.0" ESTIMABLE="YES" MEAN_1="119.0" MEAN_2="157.0" MODIFIED="2012-01-03 18:37:48 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1123" SD_1="15.0" SD_2="14.0" SE="4.188277291043021" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="34.89526639085734"/>
<CONT_DATA CI_END="48.93918319838421" CI_START="-48.93918319838421" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="177.0" MEAN_2="177.0" MODIFIED="2012-01-03 18:37:59 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1125" SD_1="71.0" SD_2="89.0" SE="24.969429838716547" STUDY_ID="STD-Lepre-1999" TOTAL_1="32" TOTAL_2="17" WEIGHT="1.9902502323598104"/>
<CONT_DATA CI_END="89.76867033045991" CI_START="-169.7686703304599" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="213.0" MEAN_2="253.0" ORDER="1119" SD_1="139.0" SD_2="170.0" SE="66.20972188981972" STUDY_ID="STD-Martinez-Hernandez-1993" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.29047092504320426"/>
<CONT_DATA CI_END="57.40569647411769" CI_START="-67.40569647411769" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="158.0" MEAN_2="163.0" ORDER="1126" SD_1="83.0" SD_2="57.0" SE="31.840226129850272" STUDY_ID="STD-Renders-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2381506879500015"/>
<CONT_DATA CI_END="15.46423486193099" CI_START="-57.46423486193099" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="181.0" MEAN_2="202.0" MODIFIED="2012-01-03 18:38:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1127" SD_1="79.0" SD_2="67.0" SE="18.60454332301829" STUDY_ID="STD-Santos-2001" TOTAL_1="31" TOTAL_2="31" WEIGHT="3.501550816645205"/>
<CONT_DATA CI_END="28.315417739527902" CI_START="-38.3154177395279" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="155.0" MODIFIED="2012-01-03 18:38:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="256" SD_1="67.0" SD_2="78.0" SE="16.99797445377347" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" WEIGHT="4.151732558796013"/>
<CONT_DATA CI_END="4.9842256230042" CI_START="-38.9842256230042" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="181.0" MEAN_2="198.0" MODIFIED="2012-01-03 18:39:08 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="257" SD_1="107.0" SD_2="107.0" SE="11.216647752924526" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="182" WEIGHT="8.824773727053094"/>
<CONT_DATA CI_END="16.22505849876925" CI_START="-42.22505849876925" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="152.0" MODIFIED="2012-01-03 18:39:28 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="1118" SD_1="84.0" SD_2="86.0" SE="14.911018125482295" STUDY_ID="STD-UK_x002d_HARP_x002d_1-2005" TOTAL_1="65" TOTAL_2="65" WEIGHT="5.2968108985841615"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.8416529823033345" CI_END="1.3681818912761798" CI_START="0.942284523079917" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1354367533719145" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="175" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.1361438379735805" LOG_CI_START="-0.025817942062549032" LOG_EFFECT_SIZE="0.055162947955515726" METHOD="IV" MODIFIED="2013-12-18 15:30:46 +1100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.4278598622247066" P_Q="1.0" P_Z="0.18184440744741834" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1378" TOTAL_2="1362" WEIGHT="100.0" Z="1.3350975921572366">
<NAME>End-stage kidney disease</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-05 10:44:03 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="87" O_E="0.0" SE="0.0" STUDY_ID="STD-Cofan-2002" TOTAL_1="30" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-11-05 06:45:47 +1100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="0.3499127922953679"/>
<DICH_DATA CI_END="190.44254743028458" CI_START="0.6120481756320255" EFFECT_SIZE="10.796296296296296" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2797639821257047" LOG_CI_START="-0.21321439225361327" LOG_EFFECT_SIZE="1.0332747949360455" MODIFIED="2011-11-05 06:37:44 +1100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="1.4643878375523887" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" VAR="2.144431738771361" WEIGHT="0.4220734750872793"/>
<DICH_DATA CI_END="6.036853464551696" CI_START="0.13341241339313906" EFFECT_SIZE="0.8974358974358975" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7808106341425284" LOG_CI_START="-0.8748037594949756" LOG_EFFECT_SIZE="-0.046996562676223555" MODIFIED="2011-11-05 06:45:55 +1100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.9725160902460924" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" VAR="0.9457875457875458" WEIGHT="0.9569884485178042"/>
<DICH_DATA CI_END="4.255533377536525" CI_START="0.6905774786579869" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6289540011781897" LOG_CI_START="-0.1607875891114538" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2011-11-05 06:48:18 +1100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.46389811942005665" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="182" VAR="0.21520146520146516" WEIGHT="4.205862423953993"/>
<DICH_DATA CI_END="1.3467595411256692" CI_START="0.9168475135533872" EFFECT_SIZE="1.1112034632034633" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="165" LOG_CI_END="0.1292900609906314" LOG_CI_START="-0.037702888462020585" LOG_EFFECT_SIZE="0.045793586264305415" MODIFIED="2011-11-05 06:38:05 +1100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.09809248513691926" STUDY_ID="STD-ALERT-2001" TOTAL_1="1050" TOTAL_2="1052" VAR="0.009622135640336725" WEIGHT="94.06516286014556"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.907081882337559" CI_END="1.278462071500608" CI_START="0.6050977564777718" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8795422282113251" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="119" I2="38.86386916024098" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.10668784821504712" LOG_CI_START="-0.21817445729915377" LOG_EFFECT_SIZE="-0.05574330454205329" METHOD="MH" MODIFIED="2014-01-15 13:36:37 +1100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.17872902141864122" P_Q="1.0" P_Z="0.5011874048731338" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.058514297742574176" TOTALS="YES" TOTAL_1="292" TOTAL_2="290" WEIGHT="100.0" Z="0.6726226307403742">
<NAME>Acute allograft rejection</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3857985720614217" CI_START="0.27370063845093145" EFFECT_SIZE="0.8080808080808081" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.37763377431548095" LOG_CI_START="-0.5627241895266937" LOG_EFFECT_SIZE="-0.09254520760560633" ORDER="1057" O_E="0.0" SE="0.5523709228078868" STUDY_ID="STD-Sahu-2001" TOTAL_1="33" TOTAL_2="32" VAR="0.3051136363636364" WEIGHT="10.014208046970976"/>
<DICH_DATA CI_END="0.9265825372999703" CI_START="0.1982267763463072" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.03311588892212164" LOG_CI_START="-0.7028376816670673" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="1056" O_E="0.0" SE="0.3933978962347216" STUDY_ID="STD-Katznelson-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.15476190476190477" WEIGHT="17.07384950157941"/>
<DICH_DATA CI_END="2.362536192282871" CI_START="0.636643784987137" EFFECT_SIZE="1.2264150943396226" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.37337847029805943" LOG_CI_START="-0.1961034962139264" LOG_EFFECT_SIZE="0.0886374870420665" MODIFIED="2013-12-12 16:08:14 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1055" O_E="0.0" SE="0.33451652611033866" STUDY_ID="STD-Kasiske-2001" TOTAL_1="53" TOTAL_2="52" VAR="0.11190130624092888" WEIGHT="21.368030266655357"/>
<DICH_DATA CI_END="1.2267033092081503" CI_START="0.7965606718161959" EFFECT_SIZE="0.9885057471264368" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="87" LOG_CI_END="0.08873953684724425" LOG_CI_START="-0.09878113959734587" LOG_EFFECT_SIZE="-0.005020801375050797" MODIFIED="2011-12-07 10:31:26 +1100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.11015057358587114" STUDY_ID="STD-SOLAR-Study-2001" TOTAL_1="182" TOTAL_2="182" VAR="0.012133148861296413" WEIGHT="51.54391218479425"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5537752003132757" CI_END="0.248386529999838" CI_START="-0.1699334205043208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.039226554747758595" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2013-12-18 15:21:33 +1100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.4567793388199689" P_Q="1.0" P_Z="0.7131878183179052" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="66" UNITS="g/24 h" WEIGHT="99.99999999999999" Z="0.3675781394147548">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6722842869005989" CI_START="-0.2722842869005991" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.5" MODIFIED="2012-01-03 18:19:21 +1100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="1.2" SD_2="0.6" SE="0.24096579867074966" STUDY_ID="STD-Santos-2001" TOTAL_1="31" TOTAL_2="31" WEIGHT="19.613277373879303"/>
<CONT_DATA CI_END="0.23328478803539388" CI_START="-0.23328478803539388" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.3" MODIFIED="2012-01-03 18:19:46 +1100" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="0.31" SD_2="0.64" SE="0.11902503815147344" STUDY_ID="STD-Seron-2008" TOTAL_1="39" TOTAL_2="35" WEIGHT="80.38672262612069"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2013-12-18 15:21:32 +1100" MODIFIED_BY="Suetonia Palmer" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="31" UNITS="mL/min" WEIGHT="0.0" Z="0.0">
<NAME>Glomerular filtration rate</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.960964298285907" CI_START="-9.960964298285907" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="57.0" MEAN_2="58.0" MODIFIED="2012-03-05 10:45:18 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="88" SD_1="18.0" SD_2="18.0" SE="4.572004572006858" STUDY_ID="STD-Santos-2001" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-01-15 13:09:11 +1100" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-12-18 10:15:43 +1100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAooAAAIsCAYAAAB1MYh/AABsNUlEQVR42uydD2SW3///PySZJJFM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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-01-15 13:09:11 +1100" MODIFIED_BY="Suetonia Palmer" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-01-15 13:09:11 +1100" MODIFIED_BY="Suetonia Palmer" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVgAAAPpCAIAAADfB6LuAAAzmElEQVR42u3dvW4kxxmF4QEMGA4Y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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-01-19 15:16:07 +1100" MODIFIED_BY="Ann Jones">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-01-19 15:16:07 +1100" MODIFIED_BY="Ann Jones" NO="1">
<TITLE MODIFIED="2015-01-19 11:13:06 +1100" MODIFIED_BY="Ann Jones">Reader comments</TITLE>
<DATE_SUBMITTED>
<DATE DAY="18" MONTH="3" YEAR="2014"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-01-19 15:16:07 +1100" MODIFIED_BY="Ann Jones">
<P>We thank you for your appraisal of the evidence regarding the use of statins in the kidney transplant population¹. In evaluation of the ALERT trial², the predominant study examined in your review, we have a few areas of concerns regarding the general appraisal and the presentation of the available evidence.</P>
<P>Firstly, the conclusion of this review eludes that perhaps all renal transplant patients will benefit from statin therapy. We would like to highlight a few points regarding this claim. Although the ALERT study is relatively small compared to other statin studies in the general population, it is the largest trial used in this systematic review. It is important to note that annual rate of fatal or non-fatal cardiac events in the placebo group is within the range of annual rates reported in previous primary and secondary prevention studies with statins, thus this potentially suggests that renal transplant by itself is not an independent risk factor for cardiovascular disease. Furthermore, previous comparisons of the observed and expected incidences of ischemic heart disease (IHD) in a population of renal transplant recipients found that many of the risk factors defined for the Framingham cohort appear to be associated with qualitatively similar risks of IHD for renal transplant recipients³.</P>
<P>We agree that the current available evidence regarding the potential benefit of statins in reducing cardiovascular risk in the kidney transplant population requires further insight and evaluation. However, as demonstrated in the ALERT trial, the paucity of evidence suggesting a benefit is also complimented by a possible harm with the use of fluvastatin; a non-statistically significant increase risk in non-cardiovascular deaths (RR: 1.20; CI: 0.86-1.67) and fatal and non-fatal cerebrovascular events (RR 1.16; CI: 0.83-1.63)². Despite yielding non-significance in the trial, providing that commentary on the potential harms of using statins in this review would not only bring clarity as to why this area needs further evaluation, but also makes transparent the potential benefits and harms of starting a statin in this population.</P>
<P>Moreover, we would also like to highlight a few things regarding the ALERT trial. In evaluation of the endpoints (Figure 4) in the ALERT trial, there are concerns regarding the reporting and evaluation of the mortality endpoints. The analysis in Figure 4 of the trial suggests that 77 and 65 people died of non-cardiovascular death in the fluvastatin and placebo arm, respectively. It is not entirely clear to us how the authors define non-cardiovascular death. Only by using Figure 2 in the ALERT trial, does it become more apparent that fatal cerebrovascular events and other vascular deaths have been excluded from the analysis of non-cardiovascular death. We think this discrepancy under-represents the magnitude of possible harm resulting in non-cardiovascular death with the use of fluvastatin. Non-cardiovascular mortality was not evaluated in this review; however, future revisions should evaluate an endpoint inclusive of fatal cerebrovascular and other vascular deaths and reflect that it resulted in 107 vs. 84 deaths (HR: 1.28, P = 0.08) in the treatment and placebo arm, respectively. As such, it is possible there is a stronger signal for non-cardiovascular harm with the use of fluvastatin. The authors of the ALERT trial have been contacted; however, we have yet to receive further clarification. It should be noted that this discrepancy was not addressed in the risk of bias summary (Figure 3) in the review¹. It is also important to note that in the ALERT trial, 11 of the 12 patients who underwent revascularization in the first year were in the fluvastatin arm. It is possible that decreased occurrence of cardiac death and non-fatal MI in fluvastatin group is a consequence of a higher incidence of early revascularization in the fluvastatin arm.</P>
<P>Based on the evaluation of this Cochrane review, we feel that the presentation of the evidence reads in a manner that puts more emphasis on the potential benefits of statin therapy, indirectly biasing the interpretation of the over-arching message. In conclusion, we recommend the following: a) a greater emphasis should be placed on the fact that renal transplantation is potentially not an independent risk factor for ischemic heart disease b) the risk of bias summary in the review should address the reporting bias with regards to non-cardiovascular deaths found in the ALERT trial c) more transparency in the presentation of the potential harms&#8212;possible non-cardiovascular deaths and fatal and non-fatal cerebrovascular events&#8212;with using statins for primary prevention in this population. Overall, it remains unclear whether the benefit of using statins for primary prevention in renal transplant patients outweighs the potential harm. Consequently, patient specific risk factors should be evaluated on a case-by-case basis before initiating statin therapy.</P>
<OL>
<LI>Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GFM. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.:CD005019. DOI: 10.1002/14651858.CD005019.pub4</LI>
<LI>Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial. Lancet. 2003;361(9374):2024-31.</LI>
<LI>Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11:1735&#8211;43</LI>
</OL>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-01-19 11:20:34 +1100" MODIFIED_BY="Ann Jones">
<P>We thank the writers for their careful reading of this systematic review. We will consider these suggestions in any update of this review in due course.</P>
<P>GFM Strippoli</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-01-19 11:19:53 +1100" MODIFIED_BY="Ann Jones">
<P>Yvonne Huang, B.Sc. Pharm<BR/>Reza Rafizadeh, B.Sc. Pharm<BR/>Aaron M Tejani, B.Sc. Pharm, ACPR, Pharm.D<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2012-03-07 12:02:01 +1100" MODIFIED_BY="Gail Y Higgins">
<APPENDIX ID="APP-01" MODIFIED="2011-09-13 20:44:28 +1000" MODIFIED_BY="Gail Y Higgins" NO="1">
<TITLE MODIFIED="2009-02-03 15:02:51 +1100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-13 20:44:28 +1000" MODIFIED_BY="Gail Y Higgins">
<TABLE COLS="2" ROWS="4">
<TR>
<TH VALIGN="TOP">
<P>Database</P>
</TH>
<TH VALIGN="TOP">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>MeSH descriptor Kidney Transplantation explode all trees in MeSH products</LI>
<LI>kidney next (transplant* or graft* or recipient*) in All Fields in all products</LI>
<LI>renal next (transplant* or graft* or recipient*) in All Fields in all products</LI>
<LI>(#1 OR #2 OR #3)</LI>
<LI>MeSH descriptor Hydroxymethylglutaryl-CoA Reductase Inhibitors explode all trees in MeSH products</LI>
<LI>"hydroxymethylglutaryl-CoA reductase inhibitor*" in Clinical Trials</LI>
<LI>statin* or "HMG CoA*" or HMg-CoA*" in Clinical Trials</LI>
<LI>atorvastatin in Clinical Trials</LI>
<LI>cerivastatin in Clinical Trials</LI>
<LI>(dalvastatin) in Clinical Trials</LI>
<LI>fluindostatin in Clinical Trials</LI>
<LI>fluvastatin in Clinical Trials</LI>
<LI>lovastatin in Clinical Trials</LI>
<LI>pitavastatin in Clinical Trials</LI>
<LI>pravastatin in Clinical Trials</LI>
<LI>rosuvastatin in Clinical Trials</LI>
<LI>simvastatin in Clinical Trials</LI>
<LI>(mevinolin*) in Clinical Trials</LI>
<LI>monacolin* in Clinical Trials</LI>
<LI>pravachol in Clinical Trials</LI>
<LI>lipex in Clinical Trials</LI>
<LI>lipitor in Clinical Trials</LI>
<LI>zocor in Clinical Trials</LI>
<LI>lescol in Clinical Trials</LI>
<LI>mevacor in Clinical Trials</LI>
<LI>baycol in Clinical Trials</LI>
<LI>(#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26)</LI>
<LI>(#4 AND #27)</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>kidney transplantation/</LI>
<LI>exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/</LI>
<LI>"hydroxymethylglutaryl-CoA reductase inhibitor$".tw.</LI>
<LI>("HMG CoA reductase inhibitor$" or "HMG Co A reductase inhibitor$").tw.</LI>
<LI>statin$.tw.</LI>
<LI>atorvastatin.tw.</LI>
<LI>cerivastatin.tw.</LI>
<LI>dalvastatin.tw.</LI>
<LI>fluindostatin.tw.</LI>
<LI>fluvastatin.tw.</LI>
<LI>lovastatin.tw.</LI>
<LI>pitavastatin.tw.</LI>
<LI>pravastatin.tw.</LI>
<LI>rosuvastatin.tw.</LI>
<LI>simvastatin.tw.</LI>
<LI>meglutol.tw.</LI>
<LI>mevinolin$.tw.</LI>
<LI>monacolin$.tw.</LI>
<LI>Pravachol.tw.</LI>
<LI>Lipex.tw.</LI>
<LI>Lipitor.tw.</LI>
<LI>Zocor.tw.</LI>
<LI>Lescol.tw.</LI>
<LI>Mevacor.tw.</LI>
<LI>Baycol.tw.</LI>
<LI>or/2-25</LI>
<LI>and/1,26</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>exp kidney transplantation/</LI>
<LI>exp Hydroxymethylglutaryl Coenzyme a Reductase Inhibitor/</LI>
<LI>"hydroxymethylglutaryl-CoA reductase inhibitor$".tw.</LI>
<LI>("HMG CoA reductase inhibitor$" or "HMG Co A reductase inhibitor$").tw.</LI>
<LI>statin$.tw.</LI>
<LI>atorvastatin.tw.</LI>
<LI>cerivastatin.tw.</LI>
<LI>dalvastatin.tw.</LI>
<LI>fluindostatin.tw.</LI>
<LI>fluvastatin.tw.</LI>
<LI>lovastatin.tw.</LI>
<LI>pitavastatin.tw.</LI>
<LI>pravastatin.tw.</LI>
<LI>rosuvastatin.tw.</LI>
<LI>simvastatin.tw.</LI>
<LI>(meglutol or mevinolin$ or monacolin$ or pravachol or lipex or lipitor or zocor or mevacor or lescol or baycol).tw.</LI>
<LI>or/2-16</LI>
<LI>and/1,17</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-03-07 12:02:01 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2012-03-07 12:01:58 +1100" MODIFIED_BY="Narelle S Willis">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-07 12:02:01 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_16154_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Amedeo Avogadro University of Eastern Piedmont</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Medical Scientific Office</DEPARTMENT>
<ORGANISATION>Diaverum</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_3" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Diaverum Academy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_4" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="4552">
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451469</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Comparisons&lt;/p&gt;&lt;p&gt;Statins versus placebo: 17 studies (3297 participants)&lt;/p&gt;&lt;p&gt;Two or more statin regimens: 5 studies (183 participants)&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;2013 review update&lt;/p&gt;&lt;p&gt;Total included studies: 22 (99 reports)&lt;/p&gt;&lt;p&gt;Total excluded studies: 35 (42 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 1 (1 report)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 16 (62 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 8 (8 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 0&lt;/p&gt;" WIDTH="220">
<FLOWCHARTBOX TEXT="&lt;p&gt;MEDLINE, EMBASE, CENTRAL, Renal Register&lt;/p&gt;&lt;p&gt;2009 review: 247 reports screened&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 6 (14 reports)&lt;/p&gt;&lt;p&gt;Existing included studies: 7 (23 new reports)&lt;/p&gt;&lt;p&gt;New ongoing studies : 1 (1 report)&lt;/p&gt;&lt;p&gt;Excluded studies: 35 (42 reports) (not RCT, wrong population or intervention)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2013 review update&lt;/p&gt;&lt;p&gt;Renal Register: 80 reports identified&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>